0001171843-21-005409.txt : 20210803 0001171843-21-005409.hdr.sgml : 20210803 20210803094550 ACCESSION NUMBER: 0001171843-21-005409 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 47 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210803 DATE AS OF CHANGE: 20210803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RenovaCare, Inc. CENTRAL INDEX KEY: 0001016708 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 980170247 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-30156 FILM NUMBER: 211138280 BUSINESS ADDRESS: STREET 1: 9375 E. SHEA BLVD. STREET 2: SUITE 107-A CITY: SCOTTSDALE STATE: AZ ZIP: 85260 BUSINESS PHONE: 888-398-0202 MAIL ADDRESS: STREET 1: 9375 E. SHEA BLVD. STREET 2: SUITE 107-A CITY: SCOTTSDALE STATE: AZ ZIP: 85260 FORMER COMPANY: FORMER CONFORMED NAME: Janus Resources, Inc. DATE OF NAME CHANGE: 20110110 FORMER COMPANY: FORMER CONFORMED NAME: ENTHEOS TECHNOLOGIES INC DATE OF NAME CHANGE: 20001002 FORMER COMPANY: FORMER CONFORMED NAME: WHATSONLINE COM INC DATE OF NAME CHANGE: 19990722 10-Q 1 f10q_080321p.htm FORM 10-Q

NITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2021

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 000-30156

RENOVACARE, INC.

(Exact name of registrant as specified in its charter)

Nevada		98-0384030
(State or other jurisdiction of incorporation)		(I.R.S. Employer Identification No.)

9375 E. Shea Blvd., Suite 107-A Scottsdale, AZ 85260
	(Address of principal executive offices)

888-398-0202

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company", and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated Filer	x	(Do not check if a smaller reporting company)
Smaller reporting company	x	Emerging Growth Company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in 12b-2 of the Exchange Act): Yes ¨ No x

As of August 2, 2021, the registrant had 87,352,364 shares of its common stock, par value $0.00001 per share, issued and outstanding.

RENOVACARE, INC.

FORM 10-Q

For The Quarter Ended June 30, 2021

TABLE OF CONTENTS

		Page #
PART I - FINANCIAL INFORMATION

Item 1.	Financial Statements
	Consolidated Balance Sheets		1
	Consolidated Statements of Operations		2
	Consolidated Statements of Stockholders’ Equity		3
	Consolidated Statements of Cash Flows		4
	Notes to Consolidated Financial Statements		5

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations		13

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		18

Item 4.	Controls and Procedures		18

PART II - OTHER INFORMATION

Item 1.	Legal Proceedings		19

Item 1A.	Risk Factors		20

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		21

Item 6.	Exhibits		21

Signatures			22

PART I

Item 1. Financial Statements

RENOVACARE, INC. AND SUBSIDIARY

CONSOLIDATED BALANCE SHEETS


	June 30,			December 31,
	2021			2020
ASSETS	(Unaudited)
Current assets
Cash	$	4,342,978		$	7,412,969
Prepaid expenses		466,468			566,275
Total current assets		4,809,446			7,979,244

Equipment, net of accumulated depreciation of $8,308 and $3,584, respectively		33,916			38,640
Intangible assets		152,854			152,854
Security Deposit		7,995			7,995
Right of Use Asset		53,492			79,462
Other Assets		94,247			137,749
Total assets	$	5,151,950		$	8,395,944

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities
Accounts payable and accrued liabilities	$	165,476		$	1,237,437
Lease liability - current		51,132			51,125
Total current liabilities		216,608			1,288,562
Lease Liability - long term		4,433			28,607
Total liabilities		221,041			1,317,169

Commitments and contingencies

Stockholders' equity
Preferred stock: $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding		-			-
Common stock: $0.00001 par value; 500,000,000 shares authorized, 87,352,364 shares issued and outstanding at June 30, 2021 and December 31, 2020		874			874
Additional paid-in capital		36,127,419			36,846,082
Retained deficit		(31,197,384	)		(29,768,181	)
Total stockholders' equity		4,930,909			7,078,775
Total liabilities and stockholders' equity	$	5,151,950		$	8,395,944

(See accompanying notes to unaudited consolidated financial statements)

RENOVACARE, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)


	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2021			2020			2021			2020
Revenue	$	-		$	-		$	-		$	-

Operating expenses
Research and development		704,569			1,347,005			1,758,862			1,539,778
General and administrative		400,810			1,697,476			(136,234	)		2,733,042
Total operating expenses, net		1,105,379			3,044,481			1,622,628			4,272,820
Loss from operations		(1,105,379	)		(3,044,481	)		(1,622,628	)		(4,272,820	)

Other income
Interest income		2,615			32,888			2,622			86,474
Other income		190,803			-			190,803			-
Total other income		193,418			32,888			193,425			86,474
Net loss	$	(911,961	)	$	(3,011,593	)	$	(1,429,203	)	$	(4,186,346	)

Basic and Diluted Loss per Common Share	$	(0.01	)	$	(0.03	)	$	(0.02	)	$	(0.05	)

Weighted average number of common shares outstanding - basic and diluted		87,352,364			87,352,364			87,352,364			87,352,364

(See accompanying notes to unaudited consolidated financial statements)

RENOVACARE, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)


FOR THE SIX MONTHS ENDED JUNE 30, 2021	Common Stock				Additional			Retained			Total Stockholders'
	Shares		Amount		Paid-in Capital			Deficit			Equity
Balance, December 31, 2020		87,352,364	$	874	$	36,846,082		$	(29,768,181	)	$	7,078,775
Stock based compensation due to common stock purchase options		-		-		352,063			-			352,063
Reversal of stock based compensation due to common stock purchase option cancellations		-		-		(1,248,575	)		-			(1,248,575	)
Net loss for the three months ended March 31, 2021		-		-		-			(517,242	)		(517,242	)
Balance, March 31, 2021		87,352,364		874		35,949,570			(30,285,423	)		5,665,021
Stock based compensation due to common stock purchase options		-		-		243,979			-			243,979
Reversal of stock based compensation due to common stock purchase option cancellations		-		-		(66,130	)		-			(66,130	)
Net loss for the three months ended June 30, 2021		-		-		-			(911,961	)		(911,961	)
Balance, June 30, 2021		87,352,364	$	874	$	36,127,419		$	(31,197,384	)	$	4,930,909

FOR THE SIX MONTHS ENDED JUNE 30, 2020

Balance, December 31, 2019		87,352,364	$	874	$	32,378,833		$	(20,219,845	)	$	12,159,862
Stock based compensation due to common stock purchase options		-		-		465,763			-			465,763
Net loss for the three months ended March 31, 2020		-		-		-			(1,174,753	)		(1,174,753	)
Balance, March 31, 2020		87,352,364		874		32,844,596			(21,394,598	)		11,450,872
Stock based compensation due to common stock purchase options		-		-		1,586,522			-			1,586,522
Net loss for the three months ended June 30, 2020		-		-		-			(3,011,593	)		(3,011,593	)
Balance, June 30, 2020		87,352,364	$	874	$	34,431,118		$	(24,406,191	)	$	10,025,801

(See accompanying notes to unaudited consolidated financial statements)

RENOVACARE, INC. AND SUBSIDIARY

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)


	Six Months Ended June 30,
	2021			2020
Cash flows used in operating activities
Net loss	$	(1,429,203	)	$	(4,186,346	)
Adjustments to reconcile net loss to net cash flows used in operating activities
Depreciation expense		4,724			-
Stock based compensation expense		(675,163	)		2,052,285
Amortization of right of use asset		25,970			-
Changes in operating assets and liabilities:
(Increase) decrease in prepaid expenses and other assets		99,807			(301,685	)
Increase (decrease) in accounts payable		(1,071,961	)		497,738
Increase (decrease) in accounts payable - related parties		-			18,823
Increase (decrease) in lease liability		(24,165	)		-
Net cash flows used in operating activities		(3,069,991	)		(1,919,185	)

Cash flows from investing activity
Decrease (increase) in security deposit		-			(7,995	)
Net cash flows from investing activity		-			(7,995	)

Decrease in cash		(3,069,991	)		(1,927,180	)

Cash at beginning of period		7,412,969			12,185,248

Cash at end of period	$	4,342,978		$	10,258,068

(See accompanying notes to unaudited consolidated financial statements)

RENOVACARE, INC. AND SUBSIDIARY

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Note 1. Organization, Overview of Operations, Basis of Presentation, Liquidity, Recent Accounting Standards and Earnings (Loss) Per Share

Organization

RenovaCare, Inc. was incorporated on July 14, 1983 in the State of Utah under the name Far West Gold, Inc., and changed its domicile to Nevada in 1997. On January 7, 2014, the Company changed its name at the time from “Janus Resources, Inc.” to “RenovaCare, Inc.” so as to more fully reflect its current operations and business, and changed its trading symbol to “RCAR” effective as of January 9, 2014.

The Company has an authorized capital of 500,000,000 shares of $0.00001 par value common stock, of which 87,352,364 shares are outstanding as of June 30, 2021, and 10,000,000 shares of $0.0001 par value preferred stock, of which none are outstanding.

Overview of Operations

RenovaCare, Inc., through its wholly owned subsidiary, RenovaCare Sciences Corp. is a development-stage company focusing on the research, development and commercialization of autologous (using a patient’s own cells) cellular therapies that can be used for medical and aesthetic applications.

On July 12, 2013, the Company completed the acquisition of its flagship technologies (collectively, the “CellMist^TMSystem”). The CellMist™ System is a cell isolation procedure that enzymatically renders stem cells from the patient’s own skin or other tissues. The resulting stem cell suspension is administered topically from the Company’s novel solution sprayer device (the “SkinGun^TM”) as a cell therapy onto wounds including burns to facilitate healing.

In August 2019, the Company was awarded a continuation of a patent allowing the SkinGun^TM to be used to spray all varieties of tissues and cells, thus allowing for its potential application in the regeneration of tissues and organs, beyond skin; and, in November 2020, the Company was issued two new patents encompassing improvements to the SkinGun™, expanding its potential application beyond the surgical setting into the field, and allowing the use of liquid suspension solutions to include drugs, hormones, and other useful agents.

On May 6, 2021 the Food and Drug Administration gave full-approval of the Company’s Investigational Device Exemption (IDE) application to proceed with initial clinical testing of the CellMist™ System and SkinGun™ spray device in adult burn patients.

The Company has four United States patents and patents in Germany, Australia, Canada, and Europe, with the European patent being validated in France, Germany, Italy, Netherlands, Spain, Switzerland/Lichtenstein, and United Kingdom. The Company also has patent applications pending in the United States and in multiple countries.

The Company has six allowed trademarks in the United States and two pending applications. Globally, the Company has two European registered trademarks, two United Kingdom trademarks, two pending in Canada, and one allowed and one pending in Japan.

Improvements in the design and efficiency of the CellMist™ System including a closed, automated cell isolation device and the SkinGun™ spray device are in development with StemCell Systems (Berlin, Germany), the Company’s R&D innovation partner. The Company is adapting its core technologies for possible use in other clinical indications. The Company is also developing the cell isolation and spray gun devices as stand-alone 510(k)-cleared products for isolation of cells from other tissues and spraying other solutions of medical importance.

The Company does not have any commercialized products. The Company's activities have consisted principally of performing research and development activities and raising capital to support such activities. The Company has enlisted the assistance of several Contract Manufacturing Organizations (CMO) to manufacture clinical supplies including components of the CellMist System™ and the electronic SkinGun™ spray devices in compliance with FDA’s guidance for current Good Manufacturing Practices (cGMP) and Contract Research Organizations (CRO) to test and validate the Company’s products and processes and to conduct clinical trials that evaluate initially the safety and feasibility of an autologous skin cell therapy using the Company’s products to facilitate burn wound healing. These development activities are subject to significant risks and uncertainties, including possible failure of preclinical and clinical testing. The Company has not generated any revenue and has sustained recurring losses and negative cash flows from operations since inception. The Company expects to incur losses as it continues development of its products and technologies and expects that it will need to raise additional capital through partnerships or the sale of its securities to accomplish its business plan. Failing to secure such additional funding before achieving sustainable revenue and profit from operations poses a significant risk. The Company's ability to fund the development of its cellular therapies depends on the amount and timing of cash receipts from future financing activities. There can be no assurance as to the availability or terms upon which such financing and capital might be available.

Basis of Presentation

The accompanying unaudited interim consolidated financial statements of RenovaCare, Inc. and Subsidiary (the “Company”) as of June 30, 2021, and for the three and six months ended June 30, 2021 and 2020 have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. These Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2020 included in our Annual Report on Form 10-K filed with the SEC on March 31, 2021.

The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Consolidated Financial Statements and accompanying disclosures. Actual results may differ from those estimates. The accompanying unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s consolidated financial position as of June 30, 2021, results of operations and stockholders’ equity for the three and six months ended June 30, 2021 and 2020, and cash flows for the six months ended June 30, 2021 and 2020. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.

Liquidity

As of June 30, 2021, the Company had $4,342,978 of cash on hand and cash equivalents, and working capital of $4,592,838. As a result, the Company believes it currently has sufficient cash to meet its funding requirements over the next twelve months following the issuance of this Quarterly Report on Form 10-Q. However, the Company has experienced and continues to experience negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The Company expects that it may need to raise additional capital to accomplish its business plan over the next several years. There can be no assurance as to the availability or terms upon which such financing and capital might be available. See “Overview of Operations” above.

Additionally, there is uncertainty relating to the full impact of the COVID-19 pandemic on the Company’s operations and capital requirements. Should financing when needed be unavailable or prohibitively expensive or the COVID-19 pandemic continue, it may adversely affect the Company’s ability to (i) retain employees and consultants; (ii) obtain additional financing on terms acceptable to the Company, if at all; (iii) delay regulatory submissions and approvals; (iv) delay, limit or preclude the Company from the operation of clinical study sites and testing laboratories; (v) delay, limit or preclude the Company from achieving technology or product development goals, milestones, or objectives; and (vi) preclude or delay entry into joint venture or partnership arrangements. The occurrence of any one or more of such events may affect the Company’s ability to continue on its pathway to commercialization of its technology or products.

Recent Accounting Standards

Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board's Accounting Standards Codification.

The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion other than as discussed above. The Company believes that none of the new standards will have a significant impact on the financial statements.

Earnings (Loss) Per Share

The Company presents both basic and diluted earnings per share ("EPS") amounts. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. The Company has not included the effects of warrants, stock options and convertible debt on net loss per share because to do so would be antidilutive.

Following is the computation of basic and diluted net loss per share for the three and six months ended June 30, 2021 and 2020:


	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2021			2020			2021			2020
Basic and Diluted EPS Computation
Numerator:
Loss available to common stockholders'	$	(911,961	)	$	(3,011,593	)	$	(1,429,203	)	$	(4,186,346	)
Denominator:
Weighted average number of common shares outstanding		87,352,364			87,352,364			87,352,364			87,352,364
Basic and diluted EPS	$	(0.01	)	$	(0.03	)	$	(0.02	)	$	(0.05	)

The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:
Stock options		3,089,999			4,788,071			3,089,999			4,788,071
Warrants		12,296,912			12,296,912			12,296,912			12,296,912
Total shares not included in the computation of diluted losses per share		15,386,911			17,084,983			15,386,911			17,084,983

Note 2. Prepaid Expenses

Prepaid expenses consist of the following:

Prepaid Expenses
	June 30,		December 31,
	2021		2020
Prepaid insurance	$	-	$	54,180
Prepaid stock options for services		87,001		86,999
Prepaid professional fees		65,000		65,000
Prepaid research and development expense		296,196		289,746
Other prepaid costs		18,271		70,350
Total prepaid expenses	$	466,468	$	566,275

Note 3. Equity

2013 Long-Term Incentive Plan

On June 20, 2013, the Company’s Board of Directors (the “Board”) adopted the 2013 Long-Term Incentive Plan (the “2013 Plan”) and on November 15, 2013, a stockholder owning a majority of the Company’s issued and outstanding stock approved adoption to the 2013 Plan. Pursuant to the terms of the 2013 Plan, an aggregate of 20,000,000 shares of the Company’s common stock have been reserved for issuance to the Company’s officers, directors, employees and consultants in order to attract and hire key technical personnel and management. Options granted to employees under the 2013 Plan, including directors and officers who are employees, may be incentive stock options or non-qualified stock options; options granted to others under the 2013 Plan are limited to non-qualified stock options. As of June 30, 2021, there were 16,668,266 shares available for future grants.

The 2013 Plan is administered by the Board or a committee designated by the Board. Subject to the provisions of the 2013 Plan, the Board has the authority to determine the officers, employees and consultants to whom options will be granted, the number of shares covered by each option, vesting rights and the terms and conditions of each option that is granted to them; however, no person may be granted options to purchase more than 2,000,000 shares in any one fiscal year under the 2013 Plan, and the aggregate fair market value (determined at the time the option is granted) of the shares with respect to which incentive stock options are exercisable for the first time by an optionee during any calendar year cannot exceed $100,000. Options granted pursuant to the 2013 Plan are exercisable no later than ten years after the date of grant.

The exercise price per share of common stock for options granted under the 2013 Plan is the fair market value of the Company's common stock on the date of grant, using the closing price of the Company's common stock on the last trading day prior to the date of grant, except for incentive stock options granted to a holder of ten percent or more of the Company's common stock, for whom the exercise price per share will not be less than 110% of the fair market value. No option can be granted under the 2013 Plan after June 20, 2023.

Common Stock

At June 30, 2021, the Company had 500,000,000 authorized shares of common stock with a par value of $0.00001 per share and 87,352,364 shares of common stock outstanding.

During the three and six months ended June 30, 2021 and 2020, the Company did not have any common stock transactions.

Warrants

The Company has issued warrants to purchase common stock at various exercise prices in connection with loan agreements and private placements. The following table summarizes information about warrants outstanding at June 30, 2021 and December 31, 2020:

Summary of warrants outstanding
	Shares of Common Stock Issuable from Warrants Outstanding as of				Weighted
	June 30,		December 31,		Average
Description	2021		2020		Exercise Price		Expiration
Series E		584,416		584,416	$	1.54	September 9, 2021
Series F		7,246		7,246	$	3.45	February 23, 2022 & March 9, 2022
Series G		460,250		460,250	$	2.68	July 21, 2022
Series H		910,000		910,000	$	2.75	October 16, 2022
Series I		10,335,000		10,335,000	$	2.00	November 26, 2025
Total		12,296,912		12,296,912

Stock Options

The following table summarizes stock option activity for the six months ended June 30, 2021:

Summary of stock option activity
	Number of Options			Weighted Average Exercise Price ($)		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value ($)
Outstanding at December 31, 2020		5,895,570			2.45		5.14		3,376,267
Forfeited		(2,805,571	)		2.74
Outstanding at June 30, 2021		3,089,999			2.18		4.96		4,177,775
Vested and exercisable at June 30, 2021		2,427,499			1.90		4.93		3,972,400

The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected term of the stock options. The ranges of assumptions used in the Black-Scholes Model during the six months ended June 30, 2020 is set forth in the table below:


	Six Months Ended
	June 30, 2020
Risk-free interest rate	0.034%	-	1.67%
Expected term in years	3.25	–	4.98
Weighted Avg. Expected Volatility	105.71%	–	106.88%
Expected dividend yield		0%

The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term. Estimated volatility is a measure of the amount by which the stock price is expected to fluctuate each year during the term of an award. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. The average expected life is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Future stock-based compensation may significantly differ based on changes in the fair value of our Common Stock and our estimates of expected volatility and the other relevant assumptions.

The following table sets forth the share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time, that were recorded in the Company’s Statements of Operations for the three and six months ended June 30, 2021 and 2020:


	Three Months Ended June 30,					Six Months Ended June 30
	2021			2020		2021			2020
Research and development	$	228,625		$	631,876	$	507,438		$	631,876
General and administrative		(29,026	)		954,646		(1,182,601	)		1,420,409
Total	$	(199,599	)	$	1,586,522	$	(675,163	)	$	2,052,285

Three and Six Months Ended June 30, 2021

During the first half of 2021, certain individuals resigned from the Company resulting in the forfeiture and cancellation of 2,805,571 options. Compensation expense was recorded on some of these options prior to their full vesting. As a result, during the three and six months ended June 30, 2021, the Company recognized $66,130 and $1,248,575, respectively, of reversals of the prior recognized compensation expense related to the cancelled options. During the three and six months ended June 30, 2021, the expense recognized for options still in their vesting period totaled $265,726 and $639,541, respectively.

Note 4. Leases

In February 2020, the Company entered into a two-year lease for office premises located at 4 Becker Farm Road, Suite 105, Roseland, New Jersey. Monthly base rent in year one of the lease is $4,356; and $4,459 in year 2 of the lease. The term (and payment of the monthly rent) commenced upon completion of the landlord’s work on August 1, 2020.

The Company’s existing Lease is not subject to any restrictions or covenants which preclude its ability to pay dividends, obtain financing, or enter into additional Lease’s.

As of June 30, 2021, the Company has not entered into any leases which have not yet commenced which would entitle the Company to significant rights or create additional obligations.

The Company does not have any finance leases.

Supplemental lease information as of June 30, 2021:


	As of June 30, 2021			As of December 31, 2020

Operating lease right-of-use asset	$	53,492		$	79,462

Current maturities of operating lease	$	51,132		$	51,125
Non-current operating lease		4,433			28,607
Total operating lease liabilities	$	55,565		$	79,732

Weighted Average remaining lease term (in years):		1.09			1.6
Discount rate:		7.0	%		7.0	%
Right-of-use asset obtained in exchange for lease obligation				$	98,402

Supplemental cash flow information for the six months ended June 30, 2021:

Cash paid for amount included in the measurement of lease liabilities for operating lease

26,136

The Company leases office space under a non-cancellable operating lease expiring in 2022. Future lease payments included in the measurement of lease liabilities on the balance sheet at June 30, 2021 for future periods are as follows:

Schedule of future lease payments
Years ending December 31, 2021,
2021 (Remaining)	$	26,652
2022		31,213
Total future minimum lease payments		57,864
Less imputed interest		(2,299	)
Total	$	55,565

Note 5. Commitments and Contingencies

Stem Cell Systems

In connection with the Company’s anticipated regulatory filings, the Company has engaged StemCell Systems GmbH (“StemCell Systems”) to provide it with prototypes and related documents under various agreements. On July 1, 2020, the Company and StemCell Systems entered into a Strategic R&D Agreement (the “Strategic Agreement”) having an initial term of three years with successive one-year extensions unless earlier terminated. The Strategic Agreement includes a $27,000 monthly fee to be paid to StemCell Systems along with any additional expenses incurred. The Company, StemCell Systems and certain affiliates of StemCells entered into a Rights of First Refusal and Corporate Opportunities Agreement (the “ROFR Agreement”). Pursuant to the ROFR Agreement, (i) in the event a StemCell Systems stockholder receives an offer from a third party to acquire the StemCell Systems stockholders ownership interest, the Company shall have ten business days to purchase such ownership, and (ii) if during the terms of the Strategic Agreement, any StemCell Systems inventions, with respect to skin, burns and wounds, designs, inventions and among other things, whether or not patentable, copyrightable or otherwise legally protectable are discovered by StemCell Systems, the Company shall have the first option to negotiate mutually agreeable terms for the Company’s acquisition or licensing of the StemCell Systems inventions. Pursuant to these engagements the Company incurred expenses of approximately $128,000 and $122,000 during the three months ended June 30, 2021 and 2020, respectively; and $248,000 and $199,000 during the six months ended June 30, 2021 and 2020, respectively.

SEC Complaint

On May 28, 2021 the SEC filed a civil complaint naming the Company and Harmel S. Rayat, RenovaCare Chairman as defendants (the “Complaint”). The Complaint charges Mr. Rayat and the Company with violating the antifraud provisions of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and also charges Mr. Rayat with aiding and abetting the Company's violations of those provisions. The complaint also charges the Company with violating the reporting provisions of Exchange Act Section 15(d) and Rules 15d-11 and 12b-20 thereunder. The SEC seeks permanent injunctions and civil penalties against Mr. Rayat and the Company, and officer-and-director and penny stock bars against Mr. Rayat.

The Company believes that the claims asserted in the Complaint are without merit and intends to defend this matter vigorously. Most, if not all, of the cost to defend the Company and Mr. Rayat is expected to be covered by insurance. However, because of the inherent uncertainty as to the outcome of this proceeding, the Company is unable, at this time, to estimate the possible impact of the outcome of this matter nor provide assurance that the available insurance coverage will be sufficient to see the Complaint through to resolution.

Class Action Complaints

On July 16 and July 21, 2021, two purported shareholders of the Company filed putative class actions in the United States District Court for the District of New Jersey against the Company and certain of its current and former executive officers (captioned Gabrielle A. Boller, Individually and On Behalf of All Others Similarly Situated v. RenovaCare, Inc., Harmel Rayat, and Thomas Bold, No. 2:21-cv-13766-SDW-ESK (“Boller”), and Michael Solakian, Individually and On Behalf of All Others Similarly Situated v. RenovaCare, Inc., Harmel Rayat, and Thomas Bold, No. 2:21-cv-13930 (“Solakian”), respectively). The complaints in Boller and Solakian were brought both individually and on behalf of a putative class of the Company’s stockholders, claiming that in connection with the facts and circumstances underlying the allegations in the SEC Complaint, the Company engaged in fraudulent conduct and made false and misleading statements of material fact or omitted to state material facts necessary to make the statements made not misleading. Both Boller and Solakian seek to declare the action to be a class action and monetary damages, including costs and expenses, and award of reasonable attorneys’ fees, expert fees, and other costs, and such other relief as the Court may deem just and proper.

The Company believes that the claims asserted in Boller and Solakian and any other Class Actions derived from the SEC Complaint are without merit and intends to defend itself vigorously. Based on the early stages of these legal proceedings, and the inherent uncertainty as to their outcome, at this time, the Company is not able to reasonably estimate a possible range of loss, if any, that may result from the allegations set forth in the complaints filed in the Class Actions.

Note 6. Related Party Transactions

During the three and six months ended June 30, 2020, Talia Jevan Properties, Inc. made payments totaling $5,287 and $10,811, respectively, to Stephen Yan-Klassen, former CFO who resigned in 2020, for his salary on behalf of the Company. Talia Jevan Properties, Inc. is a related party of Harmel S. Rayat, Chairman of the Board.

On August 1, 2013, the Company entered into a consulting agreement, as amended on May 1, 2016, with Jatinder Bhogal, an individual owning in excess of 5% of the Company’s issued and outstanding shares of common stock, to provide consulting services to the Company through his wholly owned company, Vector Asset Management, Inc. (“VAMI”). Pursuant to the consulting agreement, VAMI assisted the Company with identifying subject matter experts in the medical device and biotechnology industries and assisted the Company with its ongoing research, development and eventual commercialization of its Regeneration Technology. Pursuant to an amendment dated May 1, 2016, the VAMI monthly consulting fee was increased from $5,000 to $6,800. On June 22, 2018, the Company and VAM entered into an Executive Consulting Agreement (the “ECA”) pursuant to which Mr. Bhogal served as the Company’s Chief Operating Officer. The ECA supersedes the prior consulting agreement. Pursuant to the ECA, VAMI received compensation of $120,000 per year. On July 1, 2020 the Company amended the ECA and paid VAMI $4,000 per month through November 30, 2020 and $200 per month thereafter until May 31, 2021 at which time the ECA as amended expired. For consulting services provided by VAMI, during the three months ended June 30, 2021 and 2020, the Company recognized expenses of $400 and $30,000, respectively; and $1,000 and $60,000 during the six months ended June 30, 2021 and 2020, respectively. Jatinder Bhogal resigned as the Company’s COO effective June 30, 2020.

Note 7. Subsequent Events

Management has reviewed material events subsequent of the period ended June 30, 2021 and prior to the filing of financial statements in accordance with FASB ASC 855 “Subsequent Events”.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward-Looking Statements

This discussion and analysis of financial condition and results of operations is based upon and should be read in conjunction with the unaudited interim consolidated financial statements of RenovaCare, Inc. (“RenovaCare”) and its wholly-owned subsidiary (collectively with RenovaCare, “we,” “our,” “us,” or the “Company”), appearing elsewhere in this Quarterly Report on Form 10-Q, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of any contingent liabilities at the financial statement date and reported amounts of revenue and expenses during the reporting period. On an on-going basis the Company reviews its estimates and assumptions. The estimates were based on historical experience and other assumptions that the Company believes to be reasonable under the circumstances. Actual results are likely to differ from those estimates under different assumptions or conditions, but we do not believe such differences will materially affect our financial position or results of operations. Critical accounting policies, the policies the Company believes are most important to the presentation of its financial statements and require the most difficult, subjective and complex judgments, are outlined below in “Critical Accounting Policies,” and have not changed significantly since 2020.

This Quarterly Report on Form 10-Q also contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, as well as information relating to the Company that is based on management's exercise of business judgment and assumptions made by and information currently available to management. Although forward-looking statements in this Quarterly Report on Form 10-Q reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. When used in this document and other documents, releases and reports released by us, the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “the facts suggest” and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect our current view of future events and are subject to certain risks and uncertainties as noted below. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual results could differ materially from those anticipated in these forward-looking statements. Actual events, transactions and results may materially differ from the anticipated events, transactions or results described in such statements. Although we believe that our expectations are based on reasonable assumptions, we can give no assurance that our expectations will materialize. Many factors could cause actual results to differ materially from our forward-looking statements and unknown, unidentified or unpredictable factors could materially and adversely impact our future results. We undertake no obligation and do not intend to update, revise or otherwise publicly release any revisions to our forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of any unanticipated events. Several of these factors include, without limitation:

	·	our ability to meet requisite regulations or receive regulatory approvals in the United States, and our ability to retain any regulatory approvals that we may obtain; and the absence of adverse regulatory developments in the United States and abroad;
	·	new entrance of competitive products or further penetration of existing products in our markets;
	·	results of our clinical trials;
	·	failure of our products to gain market acceptance;
	·	the cost and success of our development programs;
	·	our failure to obtain financing as, if and when needed, on commercially acceptable terms;
	·	our failure to attract and retain qualified personnel;
	·	our failure to adequately manage our growth and expansion;
	·	the effect on us from adverse publicity related to our products or the Company itself; and
	·	our failure to defend against any adverse claims relating to our intellectual property.

The safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, apply to forward-looking statements made by us. The reader is cautioned that no statements contained in this Form 10-Q should be construed as a guarantee or assurance of future performance or results. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors, including, without limitation, the risks described in this report and matters described in this report generally. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this filing will in fact occur.

Overview

We are a development-stage biotechnology and medical device company focusing on the research, development and commercialization of autologous (using a patient's own cells) cellular therapies that can be used for medical and aesthetic applications. The Company does not have any commercialized products. The Company's activities have consisted principally of performing research and development activities, business development efforts, and raising capital to support such activities.

The Company, through its wholly owned subsidiary, RenovaCare Sciences Corp., owns the CellMist™ System which is a cell isolation procedure that enzymatically renders stem cells from the patient’s own skin or other tissues. The resulting stem cell suspension is administered topically with our SkinGun™ spray device as a cell therapy onto wounds including burns to facilitate healing.

In May 2021, the Company announced that the US Food and Drug Administration (FDA) fully approved the Company’s Investigational Device Exemption (IDE) application to conduct a clinical trial that will evaluate the safety and feasibility of autologous skin and pluripotent stem cells rendered by its manual CellMist™ System from donor skin and applied topically with the electronic SkinGun™ spray device for treatment of acute burn wounds. The clinical trial protocol is an open-label single-arm clinical study that will enroll 14 adult human burn subjects with partial-thickness, second-degree thermal burn wounds covering between 10% and 30% total body surface area. The Company expects to conduct the clinical study at up to four (4) U.S. burn centers. Currently, the clinical trial is activated and screening patients at its first burn center.

The development of our new closed, automated cell isolation device for the CellMist^TM System is in the early stage, and we expect significant time and resources will be devoted to develop our technology and determine the commercial feasibility of the product. Research and development of new technologies involve a high degree of risk, and there is no assurance that our development activities will result in a commercially viable product. The long-term profitability of our operations will be, in part, directly related to the cost and success of our development programs, which may be affected by a number of factors.

The Company has not generated any revenue and has sustained recurring losses and negative cash flows from operations since inception. The Company expects to incur losses as it continues development of its products and technologies and expects that it will need to raise additional capital through partnerships or the sale of its securities to accomplish its business plan. Failing to secure such additional funding before achieving sustainable revenue and profit from operations poses a significant risk. The Company's ability to fund the development of its cellular therapies depends on the amount and timing of cash receipts from future financing activities. There can be no assurance as to the availability or terms upon which such financing and capital might be available.

Additionally, there is significant uncertainty relating to the full impact of the COVID-19 pandemic on the Company’s operations and capital requirements. Should financing when needed be unavailable or prohibitively expensive or the COVID-19 pandemic continue, it may adversely affect the Company’s ability to (i) retain employees and consultants; (ii) obtain additional financing on terms acceptable to the Company, if at all; (iii) delay regulatory submissions and approvals; (iv) delay, limit or preclude the Company from the operation of clinical study sites and testing laboratories; (v) delay, limit or preclude the Company from achieving technology or product development goals, milestones, or objectives; and (vi) preclude or delay entry into joint venture or partnership arrangements. The occurrence of any one or more of such events may affect the Company’s ability to continue its pathway to commercialization of its technology or products.

Although the Company continues to monitor the situation and may adjust policies as more information and public health guidance become available, the COVID-19 pandemic is ongoing, and its dynamic nature, including uncertainties relating to the ultimate spread of the virus, the severity of the disease, the duration of the outbreak and actions that may be taken by governmental authorities to contain the outbreak or to treat its impact, makes it difficult to assess whether there will be further impact on the development and commercialization of the Company’s technology which could have a material adverse effect on the Company’s results of operations and cash flows.

Components of Our Results of Operations

Revenue

To date we have not generated any product revenues and do not expect to generate any revenue for the foreseeable future. Our ability to generate revenue and become profitable depends upon our ability to obtain marketing approval and successfully commercialization of our CellMist^TM System.

Research and Development

Research and development (“R&D”) expenses consist primarily of costs incurred for the development of our CellMist^TM System and include:

design, pilot-scale manufacturing and pre-clinical testing of our cell isolation and SkinGun^TMspray devices.

employee-related expenses associated with our research and development activities, including salaries, benefits, travel and non-cash stock-based compensation expenses.

costs associated with quality management systems including device verification and validation testing,

and regulatory operations and regulatory compliance.

expenses incurred under agreements related to our clinical trials.

other research and development costs including contract consulting fees and non-cash stock-based compensation to contract research organizations (CROs) and other third parties.

We do not believe that it is possible at this time to accurately project total expenses required for us to reach commercialization of our CellMist^TM System. In the future, we expect that research and development expenses will increase due to our ongoing product development and approval efforts. We expense research and development costs as incurred.

General and Administrative

General and administrative expenses consist primarily of personnel costs, including non-cash stock-based compensation related to directors and employees, professional service costs including legal, accounting, and other consulting fees and other general and administrative expenses including investor relations, insurance, and facilities costs. We expect general and administrative expenses to increase in the future as we hire personnel and incur additional costs to support the expansion of our research and development activities and our operation as a public company.

Stock-Based Compensation

Expense associated with equity-based transactions is calculated and expensed in our financial statements as required pursuant to various accounting rules and is non-cash in nature. Stock compensation represents the expense associated with the amortization of our stock options.

Other Income (Expense)

Other income consists of interest income earned on our cash and cash equivalents.

Income Taxes

We have yet to generate taxable income. We have historically incurred operating losses resulting in carry forward tax losses totaling approximately $22.3 million as of December 31, 2020. We anticipate that we will continue to generate tax losses for the foreseeable future and that we will be able to carry forward these tax losses indefinitely to future taxable years. Accordingly, we do not expect to pay taxes until we have taxable income after the full utilization of our carry forward tax losses. We have provided a full valuation allowance with respect to the deferred tax assets related to these carry forward losses.

Results of Operations

Comparison of Three and Six Months Ended June 30, 2021 and June 30, 2020

Research and Development Expenses

	Three Months Ended June 30,				Increase /			Six Months Ended June 30,				Increase /
	2021		2020		(Decrease)			2021		2020		(Decrease)
Manufacturing clinical supplies⁽¹⁾	$	31,887	$	382,066	$	(350,179	)	$	248,071	$	382,066	$	(133,995	)
Personnel related⁽²⁾		115,503		80,333		35,169			269,978		171,550		98,129
Stock-based compensation⁽³⁾		228,625		631,876		(403,251	)		507,438		631,876		(124,438	)
Clinical trials⁽⁴⁾		219,601		4,400		215,201			525,957		4,400		521,557
Regulatory⁽⁵⁾		12,072		77,362		(65,290	)		21,904		88,887		(66,983	)
All other⁽⁵⁾		96,881		170,968		(74,086	)		185,814		260,999		(75,185	)
	$	704,569	$	1,347,005	$	(642,436	)	$	1,758,862	$	1,539,778	$	219,084

(1)

Manufacturing clinical supplies decreased due to completion of the pilot-scale manufacturing and validation testing of the components of the CellMist™ System and the electronic SkinGun™ spray device to be used in our clinical trials.

(2)

Personnel related expenses, including stock-based compensation, increased due to the allocation of Stem Cell Systems personnel in support of the development of our CellMist™ System.

(3)

Stock compensation expense decreased due primarily to the completion of vesting in 2020 of prior issued stock options in excess of the amounts recognized in the current year upon the continued vesting of other R&D related stock options grants.

(4)

Clinical trial expenses increased due to the addition of clinical professionals, clinical site activation costs and costs related to the preparation of our clinical trials which began in the second quarter of 2021. We expect clinical trial expenses to increase significantly in 2021 due to patient enrollment, treatment, follow-up visits, clinical sample testing and medical site monitoring.

(5)

All other expenses decreased as validation testing for the electronic SkinGun ™ concluded and we transitioned to prototype development of the cell isolation device at StemCell Systems.

General and Administrative Expenses

	Three Months Ended June 30,					Increase /			Six Months Ended June 30,					Increase /
	2021			2020		(Decrease)			2021			2020		(Decrease)
Personnel related⁽¹⁾	$	238,911		$	203,091	$	9,470		$	468,363		$	436,687	$	31,676
Stock-based compensation⁽²⁾		(29,026	)		954,646		(983,672	)		(1,182,601	)		1,420,409		(2,603,010	)
Professional and consultant fees⁽³⁾		141,682			285,021		(143,339	)		425,473			544,764		(119,291	)
All other⁽⁴⁾		49,243			254,718		(179,125	)		152,531			331,182		(178,651	)
Total G&A Expense	$	400,810		$	1,697,476	$	(1,296,666	)	$	(136,234	)	$	2,733,042	$	(2,869,277	)

(1)

Personnel related costs increased due to slightly higher headcount in the current year.

(2)

Stock compensation expense decreased due to the forfeiture and cancellation of 2,805,571 stock options as a result of the resignation of Alan Rubino, the Company’s former Chairman, President and Chief Executive Officer, the resignation of Robert Cook, the Company’s former Chief Financial Officer, and the removal, by the Company’s stockholders of Kenneth Kirkland and Lydia Evans, as members of the Company’s Board of Directors. Compensation expense was recorded on these options prior to their full vesting. As a result, the Company recognized a $66,130 and $1,314,705 reversal of the prior recognized compensation expense related to the cancelled options for the three and six months ended June 30, 2021, respectively. The G&A expense recognized for options still in their vesting period totaled $37,104 and 132,104 during the three and six months ended June 30, 2021, respectively.

(3)

Professional and consultant fees decreased due to a decrease in legal fees and accounting and auditing fees offset by an increase in fees related to our patents and trademarks.

(4)

All other costs decreased primarily due to the absence of the charitable contribution to the Office of Research at the University of Pittsburgh which the Company recognized $62,500 and $125,000 during the three and six months ended June 30, 2020.

Liquidity and Capital Resources

The Company does not have any commercialized products, has not generated any meaningful revenue since inception and has sustained recurring losses and negative cash flows since inception. The Company has incurred operating losses of $3.1 million and $2.0 million during the six months ended June 30, 2021 and 2020, respectively. The Company expects to incur losses as it continues development of its products and technologies. Historically, the Company has been funded through the sale of equity securities and debt financings. As of June 30, 2021, the Company had $4.3 million of cash. The Company believes that it currently has sufficient cash to meet its funding requirements over the next twelve months.

Net cash used in operating activities was $3.1 million during the six months ended June 30, 2021, primarily due to operating costs of $2.1 million and the payment of liabilities of approximately $1.0 million.

Net cash used in investing was $0 for the six months ended June 30, 2021 and $8 thousand for the six months ended June 30, 2020.

There was no net cash used in financing activities during the six months ended June 30, 2021 and 2020.

Fair Value of Financial Instruments and Risks

The carrying value of cash and cash equivalents, accounts payable, and contract and contribution payable, approximate their fair value because of the short-term nature of these instruments and their liquidity. It is not practical to determine the fair value of the Company’s notes payable and accrued interest due to the complex terms. Management is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments.

Market Risk Disclosures

We have not entered into derivative contracts either to hedge existing risks or for speculative purposes during the three and six months ended June 30, 2021 or year ended December 31, 2020, and the subsequent period through the date of this report.

Off-Balance Sheet Arrangements and Contractual Obligations

We do not have any off-balance sheet arrangements or contractual obligations at June 30, 2021, and the subsequent period through the date of this annual report, that are likely to have or are reasonably likely to have a material current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that have not been disclosed in our consolidated financial statements.

Recently Accounting Standards

See Note 1 to our Consolidated Financial Statements for more information regarding recent accounting standards and their impact to our consolidated results of operations and financial position.

Related Party Transactions

On August 1, 2013, the Company entered into a consulting agreement, as amended on May 1, 2016, with Jatinder Bhogal, an individual owning in excess of 5% of the Company’s issued and outstanding shares of common stock, to provide consulting services to the Company through his wholly owned company, Vector Asset Management, Inc. (“VAMI”). Pursuant to the consulting agreement, VAMI assisted the Company with identifying subject matter experts in the medical device and biotechnology industries and assisted the Company with its ongoing research, development and eventual commercialization of its Regeneration Technology. Pursuant to an amendment dated May 1, 2016, the VAMI monthly consulting fee was increased from $5,000 to $6,800. On June 22, 2018, the Company and VAM entered into an Executive Consulting Agreement (the “ECA”) pursuant to which Mr. Bhogal served as the Company’s Chief Operating Officer. The ECA supersedes the prior consulting agreement. Pursuant to the ECA, VAMI received compensation of $120,000 per year. On July 1, 2020 the Company amended the ECA and paid VAMI $4,000 per month through November 30, 2020 and $200 per month thereafter until May 31, 2021 at which time the ECA as amended expired. For consulting services provided by VAMI, during the three months ended June 30, 2021 and 2020, the Company recognized expenses of $400 and $30,000, respectively; and $1,000 and $60,000 during the six months ended June 30, 2021 and 2020, respectively. Jatinder Bhogal resigned as the Company’s COO effective June 30, 2020.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined as a process designed by, or under the supervision of, our principal executive and principal financial officers, or persons performing similar functions, and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

The Company maintains “disclosure controls and procedures,” as such term is defined under Rule 13a-15(e) and 15d-15(e) of the Exchange Act, that are designed to provide reasonable assurance that information required to be disclosed in the Company’s Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including its Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Our management conducted an evaluation of the effectiveness of the Company’s internal control over financial reporting based on the framework in “Internal Control — Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this evaluation, management concluded that our internal control over financial reporting was not effective at June 30, 2021 due to inadequate segregation of duties consistent with control objectives. Our Company’s management is comprised of a very small number of individuals resulting in a situation where limitations of segregation of duties exist. In order to remedy this situation, we would need to hire additional staff to provide greater segregation of duties. Management believes that the material weaknesses set forth above were the result of the scale of our operations and are intrinsic to our small size and that this weakness did not have a material effect on our financial statements and results of operations.

Changes in Internal Control over Financial Reporting

There were no changes in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act), or in factors that could materially affect internal controls, during the three months ended June 30, 2021, or subsequent to the date that management completed their evaluation, that materially affected, or are reasonably likely to materially affect, our internal control over financing reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

On May 28, 2021 the SEC filed a civil complaint naming the Company and Harmel S. Rayat, RenovaCare Chairman as defendants (the “Complaint”).

The SEC's complaint, regarding legacy events from over 3 years ago, alleges that in July 2017, Mr. Rayat arranged, and caused RenovaCare to pay for a promotional campaign designed to increase the company's stock price. The complaint alleges that Mr. Rayat was closely involved in directing the promotion and editing promotional materials, and arranged to funnel payments to the publisher through consultants to conceal the Company's involvement in the campaign. According to the complaint, in January 2018, OTC Markets Group, Inc. requested the Company issue a press release to explain its relationship to the promotion. The complaint alleges that Mr. Rayat and the Company then drafted and issued a press release and a Form 8-K that contained material misrepresentations and omissions denying Mr. Rayat's and the company's involvement in the promotion.

The SEC's complaint charges Mr. Rayat and the Company with violating the antifraud provisions of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and also charges Mr. Rayat with aiding and abetting the company's violations of those provisions. The complaint also charges the Company with violating the reporting provisions of Exchange Act Section 15(d) and Rules 15d-11 and 12b-20 thereunder. The SEC seeks permanent injunctions and civil penalties against Mr. Rayat and the Company, and officer-and-director and penny stock bars against Mr. Rayat.

The Company takes issue with the statements in the Complaint and intends to defend itself and its stockholders against allegations made by the SEC.

Item 1A. Risk Factors

Our results of operations and financial condition could be adversely affected by numerous risks. In addition to the other information in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors discussed in Part I, Item 1A, "Risk Factors" in our Annual Report on Form 10-K for Fiscal 2020. These are not the only risks and uncertainties facing us. Additional risks not currently known to us or that we currently believe are immaterial may also negatively impact our business, financial condition, results of operations and future prospects.

We are the subject of an SEC Complaint. Adverse developments in our ongoing proceeding and/or future legal proceedings could have a material adverse effect on our business, reputation, financial condition, results of operations or stock price.

We are currently subject to an SEC Complaint. Refer to Note 7 to our Consolidated Financial Statements and Part II, Item 1 of this Quarterly Report for additional information regarding this specific matter. We may be subject to additional investigations, arbitration proceedings, audits, regulatory inquiries and similar actions, including matters related to intellectual property, employment, securities laws, disclosures, tax, accounting, class action and product liability, as well as regulatory and other claims related to our business and our industry, which we refer to collectively as legal proceedings. We cannot predict the outcome of any particular proceeding, or whether ongoing investigations, will be resolved favorably or ultimately result in charges or material damages, fines or other penalties, enforcement actions, bars against serving as an officer or director, or practicing before the SEC, or civil or criminal proceedings against us or members of our senior management.

Legal proceedings in general, and securities and class action litigation and regulatory investigations in particular, can be expensive and disruptive. Our insurance may not cover all claims that may be asserted against us, and we are unable to predict how long the legal proceedings to which we are currently subject will continue. An unfavorable outcome of any legal proceeding may have an adverse impact on our business, financial condition and results of operations or our stock price. Any proceeding could negatively impact our reputation among our stakeholders. Furthermore, publicity surrounding ongoing legal proceedings, even if resolved favorably for us, could result in additional legal proceedings against us, as well as damage our image.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Item 6. Exhibits

Exhibit No.		Description of Exhibit
10.1		Separation and Release of Claims Agreement dated March 26, 2021, incorporated by reference and included in the Company’s Form 8-K filed on March 30, 2021.
31.1		Certification of the Principal Executive Officer pursuant to Rule 13a-14(a).*
31.2		Certification of the Principal Financial Officer pursuant to Rule 13a-14(a).*
32.1		Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

101.INS		Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

_______________

*	Filed herewith.

SIGNATURES

Pursuant to the requirements of Sections 13 or 15 (d) of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

RenovaCare, Inc.

(Registrant)

Date: August 3, 2021	By:	/s/ Dr. Kaiyo Nedd
	Name:	Dr. Kaiyo Nedd
	Title:	Chief Executive Officer
		(Principal Executive Officer)

Date: August 3, 2021	By:	/s/ Justin Frere, CPA
	Name:	Justin Frere, CPA
	Title:	Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)

EX-31.1 2 exh_311.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION PURSUANT TO RULE 13A-14(A) OR RULE 15D-14(A)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Dr. Kaiyo Nedd, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of RenovaCare, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

5.	I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 3, 2021	By:	/s/ Dr. Kaiyo Nedd
	Name:	Dr. Kaiyo Nedd
	Title:	Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 exh_312.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION PURSUANT TO RULE 13A-14(A) OR RULE 15D-14(A)

UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Justin Frere, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of RenovaCare, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
	(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

5.	I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 3, 2021	By:	/s/ Justin Frere, CPA
	Name:	Justin Frere, CPA
	Title:	Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)

EX-32.1 4 exh_321.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, as the Chief Executive Officer and the Chief Financial Officer of RenovaCare, Inc., respectively, certifies that, to the best of their knowledge and belief, the Quarterly Report on Form 10-Q for the three and six months ended June 30, 2021 that accompanies this certification fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the quarterly report fairly presents, in all material respects, the financial condition and results of operations of RenovaCare, Inc. at the dates and for the periods indicated. The foregoing certification is made pursuant to 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) and shall not be relied upon for any other purpose.

Date: August 3, 2021	By:	/s/ Dr. Kaiyo Nedd
	Name:	Dr. Kaiyo Nedd
	Title:	Chief Executive Officer and Director
		(Principal Executive Officer)


Date: August 3, 2021	By:	/s/ Justin Frere, CPA
	Name:	Justin Frere, CPA
	Title:	Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)

EX-101.SCH 5 rcar-20210630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Organization, Overview of Operations, Basis of Presentation, Liquidity, Recent Accounting Standards and Earnings (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Prepaid Expenses link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Organization, Overview of Operations, Basis of Presentation, Liquidity, Recent Accounting Standards and Earnings (Loss) Per Share (Policies) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Organization, Overview of Operations, Basis of Presentation, Liquidity, Recent Accounting Standards and Earnings (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Prepaid Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Organization, Overview of Operations, Basis of Presentation, Liquidity, Recent Accounting Standards and Earnings (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Organization, Overview of Operations, Basis of Presentation, Liquidity, Recent Accounting Standards and Earnings (Loss) Per Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Prepaid Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Equity (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Equity (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Equity (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Equity (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Leases (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 rcar-20210630_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 rcar-20210630_def.xml XBRL DEFINITION FILE EX-101.LAB 8 rcar-20210630_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Antidilutive Securities [Axis] Share-based Payment Arrangement [Member] Warrant [Member] Plan Name [Axis] N 2013 Plan [Member] Class of Warrant or Right [Axis] Series E [Member] Series F [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Series G [Member] Series H [Member] Series I [Member] Income Statement Location [Axis] Research and Development Expense [Member] Award Type [Axis] Share-based Payment Arrangement, Option [Member] General and Administrative Expense [Member] Related Party Transaction [Axis] Stem Cell Systems [Member] Related Party [Axis] Stephen Yan-Klesson Vector Asset Management, Inc [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets Cash Prepaid expenses Total current assets Equipment, net of accumulated depreciation of $8,308 and $3,584, respectively Intangible assets Security Deposit Right of Use Asset Other Assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable and accrued liabilities Lease liability - current Total current liabilities Lease Liability - long term Total liabilities Commitments and contingencies Stockholders' equity Preferred stock: $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding Common stock: $0.00001 par value; 500,000,000 shares authorized, 87,352,364 shares issued and outstanding at June 30, 2021 and December 31, 2020 Additional paid-in capital Retained deficit Total stockholders' equity Total liabilities and stockholders' equity Preferred Stock, Par Value Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Common Stock, Par Value Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Income Statement [Abstract] Revenue Operating expenses Research and development General and administrative Total operating expenses, net Loss from operations Other income Interest income Other income Total other income Net loss Basic and Diluted Loss per Common Share Weighted average number of common shares outstanding - basic and diluted Statement [Table] Statement [Line Items] Beginning balance, value Shares, Outstanding at beginning Stock based compensation due to common stock purchase options Reversal of stock based compensation due to common stock purchase option cancellations Net loss Ending balance, value Shares, Outstanding at end Statement of Cash Flows [Abstract] Cash flows used in operating activities Net loss Adjustments to reconcile net loss to net cash flows used in operating activities Depreciation expense Stock based compensation expense Amortization of right of use asset Changes in operating assets and liabilities: (Increase) decrease in prepaid expenses and other assets Increase (decrease) in accounts payable Increase (decrease) in accounts payable - related parties Increase (decrease) in lease liability Net cash flows used in operating activities Cash flows from investing activity Decrease (increase) in security deposit Net cash flows from investing activity Decrease in cash Cash at beginning of period Cash at end of period Accounting Policies [Abstract] Organization, Overview of Operations, Basis of Presentation, Liquidity, Recent Accounting Standards and Earnings (Loss) Per Share Prepaid Expenses Prepaid Expenses Equity Method Investments and Joint Ventures [Abstract] Equity Leases [Abstract] Leases Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Related Party Transactions [Abstract] Related Party Transactions Subsequent Events [Abstract] Subsequent Events Organization Overview of Operations Basis of Presentation Liquidity Recent Accounting Standards Earnings (Loss) Per Share Summary of computation of basic and diluted net loss per share Prepaid Expenses Summary of warrants outstanding Summary of stock option activity Summary of assumption of stock option activity Summary of consolidated statement of operations Schedule of supplemental lease information Leases (Details 1) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] EX-101.PRE 9 rcar-20210630_pre.xml XBRL PRESENTATION FILE XML 10 f10q_080321p_htm.xml IDEA: XBRL DOCUMENT 0001016708 2021-01-01 2021-06-30 0001016708 2021-08-02 0001016708 2021-06-30 0001016708 2020-12-31 0001016708 2021-04-01 2021-06-30 0001016708 2020-04-01 2020-06-30 0001016708 2020-01-01 2020-06-30 0001016708 us-gaap:CommonStockMember 2020-12-31 0001016708 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001016708 us-gaap:RetainedEarningsMember 2020-12-31 0001016708 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001016708 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001016708 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001016708 2021-01-01 2021-03-31 0001016708 us-gaap:CommonStockMember 2021-03-31 0001016708 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001016708 us-gaap:RetainedEarningsMember 2021-03-31 0001016708 2021-03-31 0001016708 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001016708 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001016708 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001016708 us-gaap:CommonStockMember 2021-06-30 0001016708 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001016708 us-gaap:RetainedEarningsMember 2021-06-30 0001016708 us-gaap:CommonStockMember 2019-12-31 0001016708 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001016708 us-gaap:RetainedEarningsMember 2019-12-31 0001016708 2019-12-31 0001016708 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001016708 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001016708 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001016708 2020-01-01 2020-03-31 0001016708 us-gaap:CommonStockMember 2020-03-31 0001016708 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001016708 us-gaap:RetainedEarningsMember 2020-03-31 0001016708 2020-03-31 0001016708 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001016708 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001016708 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001016708 us-gaap:CommonStockMember 2020-06-30 0001016708 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001016708 us-gaap:RetainedEarningsMember 2020-06-30 0001016708 2020-06-30 0001016708 us-gaap:StockCompensationPlanMember 2021-04-01 2021-06-30 0001016708 us-gaap:StockCompensationPlanMember 2020-04-01 2020-06-30 0001016708 us-gaap:StockCompensationPlanMember 2021-01-01 2021-06-30 0001016708 us-gaap:StockCompensationPlanMember 2020-01-01 2020-06-30 0001016708 us-gaap:WarrantMember 2021-04-01 2021-06-30 0001016708 us-gaap:WarrantMember 2020-04-01 2020-06-30 0001016708 us-gaap:WarrantMember 2021-01-01 2021-06-30 0001016708 us-gaap:WarrantMember 2020-01-01 2020-06-30 0001016708 RCAR:N2013PlanMember 2021-01-01 2021-06-30 0001016708 RCAR:SeriesEMember 2021-06-30 0001016708 RCAR:SeriesEMember 2020-12-31 0001016708 RCAR:SeriesEMember 2021-01-01 2021-06-30 0001016708 RCAR:SeriesFMember 2021-06-30 0001016708 RCAR:SeriesFMember 2020-12-31 0001016708 srt:MinimumMember RCAR:SeriesFMember 2021-01-01 2021-06-30 0001016708 srt:MaximumMember RCAR:SeriesFMember 2021-01-01 2021-06-30 0001016708 RCAR:SeriesGMember 2021-06-30 0001016708 RCAR:SeriesGMember 2020-12-31 0001016708 RCAR:SeriesGMember 2021-01-01 2021-06-30 0001016708 RCAR:SeriesHMember 2021-06-30 0001016708 RCAR:SeriesHMember 2020-12-31 0001016708 RCAR:SeriesHMember 2021-01-01 2021-06-30 0001016708 RCAR:SeriesIMember 2021-06-30 0001016708 RCAR:SeriesIMember 2020-12-31 0001016708 RCAR:SeriesIMember 2021-01-01 2021-06-30 0001016708 us-gaap:WarrantMember 2021-06-30 0001016708 us-gaap:WarrantMember 2020-12-31 0001016708 2020-01-01 2020-12-31 0001016708 srt:MinimumMember 2020-01-01 2020-06-30 0001016708 srt:MaximumMember 2020-01-01 2020-06-30 0001016708 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001016708 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001016708 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001016708 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001016708 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001016708 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001016708 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001016708 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0001016708 RCAR:StemCellSystemsMember 2021-01-01 2021-06-30 0001016708 RCAR:StephenYanKlessonMember 2020-04-01 2020-06-30 0001016708 RCAR:StephenYanKlessonMember 2020-01-01 2020-06-30 0001016708 RCAR:VectorAssetManagementIncMember 2018-06-01 2018-06-22 0001016708 RCAR:VectorAssetManagementIncMember 2021-04-01 2021-06-30 0001016708 RCAR:VectorAssetManagementIncMember 2020-04-01 2020-06-30 0001016708 RCAR:VectorAssetManagementIncMember 2021-01-01 2021-06-30 0001016708 RCAR:VectorAssetManagementIncMember 2020-01-01 2020-06-30 iso4217:USD shares iso4217:USD shares pure 0001016708 false --12-31 2021 Q2

10-Q true 2021-06-30 false 000-30156 RENOVACARE, INC. NV 98-0384030 9375 E. Shea Blvd Suite 107-A Scottsdale AZ 85260 888 398-0202 Yes Yes Non-accelerated Filer true false false 87352364

4342978

7412969

466468

566275

4809446

7979244

33916

38640

152854

7995

53492

79462

94247

137749

5151950

8395944

165476

1237437

51132

51125

216608

1288562

4433

28607

221041

1317169

0.0001

10000000

0.00001

500000000

87352364

874

36127419

36846082

-31197384

-29768181

4930909

7078775

5151950

8395944

704569

1347005

1758862

1539778

400810 1697476 -136234 2733042

1105379

3044481

1622628

4272820

-1105379

-3044481

-1622628

-4272820

2615

32888

2622

86474

190803

193418

32888

193425

86474

-911961

-3011593

-1429203

-4186346

-0.01

-0.03

-0.02

-0.05

87352364

874

36846082

-29768181

7078775

352063

-1248575 -1248575

-517242

87352364

874

35949570

-30285423

5665021

243979

-66130 -66130

-911961

87352364

874

36127419

-31197384

4930909

87352364

874

32378833

-20219845

12159862

465763

-1174753

87352364

874

32844596

-21394598

11450872

1586522

-3011593

87352364

874

34431118

-24406191

10025801

-1429203

-4186346

4724

-675163

2052285

25970

-99807

301685

-1071961

497738

18823

-24165

-3069991

-1919185

-7995

-3069991

-1927180

7412969

12185248

4342978

10258068

Note 1. Organization, Overview of Operations, Basis of Presentation, Liquidity, Recent Accounting Standards and Earnings (Loss) Per Share Organization RenovaCare, Inc. was incorporated on July 14, 1983 in the State of Utah under the name Far West Gold, Inc., and changed its domicile to Nevada in 1997. On January 7, 2014, the Company changed its name at the time from “Janus Resources, Inc.” to “RenovaCare, Inc.” so as to more fully reflect its current operations and business, and changed its trading symbol to “RCAR” effective as of January 9, 2014. The Company has an authorized capital of 500,000,000 shares of $0.00001 par value common stock, of which 87,352,364 shares are outstanding as of June 30, 2021, and 10,000,000 shares of $0.0001 par value preferred stock, of which none are outstanding. Overview of Operations RenovaCare, Inc., through its wholly owned subsidiary, RenovaCare Sciences Corp. is a development-stage company focusing on the research, development and commercialization of autologous (using a patient’s own cells) cellular therapies that can be used for medical and aesthetic applications. On July 12, 2013, the Company completed the acquisition of its flagship technologies (collectively, the “CellMistTM System”). The CellMist™ System is a cell isolation procedure that enzymatically renders stem cells from the patient’s own skin or other tissues. The resulting stem cell suspension is administered topically from the Company’s novel solution sprayer device (the “SkinGunTM”) as a cell therapy onto wounds including burns to facilitate healing. In August 2019, the Company was awarded a continuation of a patent allowing the SkinGunTM to be used to spray all varieties of tissues and cells, thus allowing for its potential application in the regeneration of tissues and organs, beyond skin; and, in November 2020, the Company was issued two new patents encompassing improvements to the SkinGun™, expanding its potential application beyond the surgical setting into the field, and allowing the use of liquid suspension solutions to include drugs, hormones, and other useful agents. On May 6, 2021 the Food and Drug Administration gave full-approval of the Company’s Investigational Device Exemption (IDE) application to proceed with initial clinical testing of the CellMist™ System and SkinGun™ spray device in adult burn patients. The Company has four United States patents and patents in Germany, Australia, Canada, and Europe, with the European patent being validated in France, Germany, Italy, Netherlands, Spain, Switzerland/Lichtenstein, and United Kingdom. The Company also has patent applications pending in the United States and in multiple countries. The Company has six allowed trademarks in the United States and two pending applications. Globally, the Company has two European registered trademarks, two United Kingdom trademarks, two pending in Canada, and one allowed and one pending in Japan. Improvements in the design and efficiency of the CellMist™ System including a closed, automated cell isolation device and the SkinGun™ spray device are in development with StemCell Systems (Berlin, Germany), the Company’s R&D innovation partner. The Company is adapting its core technologies for possible use in other clinical indications. The Company is also developing the cell isolation and spray gun devices as stand-alone 510(k)-cleared products for isolation of cells from other tissues and spraying other solutions of medical importance. The Company does not have any commercialized products. The Company's activities have consisted principally of performing research and development activities and raising capital to support such activities. The Company has enlisted the assistance of several Contract Manufacturing Organizations (CMO) to manufacture clinical supplies including components of the CellMist System™ and the electronic SkinGun™ spray devices in compliance with FDA’s guidance for current Good Manufacturing Practices (cGMP) and Contract Research Organizations (CRO) to test and validate the Company’s products and processes and to conduct clinical trials that evaluate initially the safety and feasibility of an autologous skin cell therapy using the Company’s products to facilitate burn wound healing. These development activities are subject to significant risks and uncertainties, including possible failure of preclinical and clinical testing. The Company has not generated any revenue and has sustained recurring losses and negative cash flows from operations since inception. The Company expects to incur losses as it continues development of its products and technologies and expects that it will need to raise additional capital through partnerships or the sale of its securities to accomplish its business plan. Failing to secure such additional funding before achieving sustainable revenue and profit from operations poses a significant risk. The Company's ability to fund the development of its cellular therapies depends on the amount and timing of cash receipts from future financing activities. There can be no assurance as to the availability or terms upon which such financing and capital might be available. Basis of Presentation The accompanying unaudited interim consolidated financial statements of RenovaCare, Inc. and Subsidiary (the “Company”) as of June 30, 2021, and for the three and six months ended June 30, 2021 and 2020 have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. These Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2020 included in our Annual Report on Form 10-K filed with the SEC on March 31, 2021. The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Consolidated Financial Statements and accompanying disclosures. Actual results may differ from those estimates. The accompanying unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s consolidated financial position as of June 30, 2021, results of operations and stockholders’ equity for the three and six months ended June 30, 2021 and 2020, and cash flows for the six months ended June 30, 2021 and 2020. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year. Liquidity As of June 30, 2021, the Company had $4,342,978 of cash on hand and cash equivalents, and working capital of $4,592,838. As a result, the Company believes it currently has sufficient cash to meet its funding requirements over the next twelve months following the issuance of this Quarterly Report on Form 10-Q. However, the Company has experienced and continues to experience negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The Company expects that it may need to raise additional capital to accomplish its business plan over the next several years. There can be no assurance as to the availability or terms upon which such financing and capital might be available. See “Overview of Operations” above. Additionally, there is uncertainty relating to the full impact of the COVID-19 pandemic on the Company’s operations and capital requirements. Should financing when needed be unavailable or prohibitively expensive or the COVID-19 pandemic continue, it may adversely affect the Company’s ability to (i) retain employees and consultants; (ii) obtain additional financing on terms acceptable to the Company, if at all; (iii) delay regulatory submissions and approvals; (iv) delay, limit or preclude the Company from the operation of clinical study sites and testing laboratories; (v) delay, limit or preclude the Company from achieving technology or product development goals, milestones, or objectives; and (vi) preclude or delay entry into joint venture or partnership arrangements. The occurrence of any one or more of such events may affect the Company’s ability to continue on its pathway to commercialization of its technology or products. Recent Accounting Standards Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board's Accounting Standards Codification. The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion other than as discussed above. The Company believes that none of the new standards will have a significant impact on the financial statements. Earnings (Loss) Per Share The Company presents both basic and diluted earnings per share ("EPS") amounts. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. The Company has not included the effects of warrants, stock options and convertible debt on net loss per share because to do so would be antidilutive. Following is the computation of basic and diluted net loss per share for the three and six months ended June 30, 2021 and 2020: <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z4USrGhP7ih8" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization, Overview of Operations, Basis of Presentation, Liquidity, Recent Accounting Standards and Earnings (Loss) Per Share (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt">Summary of computation of basic and diluted net loss per share</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_493_20210401__20210630_zAPyomCNYFU5" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49D_20200401__20200630_zO2DCxx4gTT2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_497_20210101__20210630_zVk6MJXwbCud" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_491_20200101__20200630_zi779N49HGn2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">June 30,</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">June 30,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2020</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2020</td></tr> <tr id="xdx_40A_eus-gaap--EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Basic and Diluted EPS Computation</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--NumeratorAbstract_i01B" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Numerator:</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--NetIncomeLoss_i02_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-size: 10pt; text-align: left; padding-left: 10pt">Loss available to common stockholders'</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(911,961</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(3,011,593</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(1,429,203</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(4,186,346</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_404_ecustom--DenominatorAbstract_i01B" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Denominator:</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i02_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 10pt">Weighted average number of common shares outstanding</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">87,352,364</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">87,352,364</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">87,352,364</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">87,352,364</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--EarningsPerShareBasicAndDiluted_i02_pdd" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted EPS</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.01</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.03</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.02</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.05</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--EarningsPerShareDilutedOtherDisclosuresAbstract_iB" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock options</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockCompensationPlanMember_znb8cSuCOer" style="font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">3,089,999</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockCompensationPlanMember_z1vioCGA8eT7" style="font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">4,788,071</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockCompensationPlanMember_z64HAwAoMBKk" style="font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">3,089,999</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockCompensationPlanMember_pdd" style="font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">4,788,071</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 10pt">Warrants</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_ziQrNI6JQZme" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">12,296,912</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zLAzCFCcfG52" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">12,296,912</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zZoaIJjAwQd6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">12,296,912</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">12,296,912</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total shares not included in the computation of diluted losses per share</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20210630_zjet6o00p0Lj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">15,386,911</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20200630_z9hhVogNm4u3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">17,084,983</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">15,386,911</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">17,084,983</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table>

Organization RenovaCare, Inc. was incorporated on July 14, 1983 in the State of Utah under the name Far West Gold, Inc., and changed its domicile to Nevada in 1997. On January 7, 2014, the Company changed its name at the time from “Janus Resources, Inc.” to “RenovaCare, Inc.” so as to more fully reflect its current operations and business, and changed its trading symbol to “RCAR” effective as of January 9, 2014. The Company has an authorized capital of 500,000,000 shares of $0.00001 par value common stock, of which 87,352,364 shares are outstanding as of June 30, 2021, and 10,000,000 shares of $0.0001 par value preferred stock, of which none are outstanding.

500000000

0.00001

87352364

10000000

0.0001

Overview of Operations RenovaCare, Inc., through its wholly owned subsidiary, RenovaCare Sciences Corp. is a development-stage company focusing on the research, development and commercialization of autologous (using a patient’s own cells) cellular therapies that can be used for medical and aesthetic applications. On July 12, 2013, the Company completed the acquisition of its flagship technologies (collectively, the “CellMistTM System”). The CellMist™ System is a cell isolation procedure that enzymatically renders stem cells from the patient’s own skin or other tissues. The resulting stem cell suspension is administered topically from the Company’s novel solution sprayer device (the “SkinGunTM”) as a cell therapy onto wounds including burns to facilitate healing. In August 2019, the Company was awarded a continuation of a patent allowing the SkinGunTM to be used to spray all varieties of tissues and cells, thus allowing for its potential application in the regeneration of tissues and organs, beyond skin; and, in November 2020, the Company was issued two new patents encompassing improvements to the SkinGun™, expanding its potential application beyond the surgical setting into the field, and allowing the use of liquid suspension solutions to include drugs, hormones, and other useful agents. On May 6, 2021 the Food and Drug Administration gave full-approval of the Company’s Investigational Device Exemption (IDE) application to proceed with initial clinical testing of the CellMist™ System and SkinGun™ spray device in adult burn patients. The Company has four United States patents and patents in Germany, Australia, Canada, and Europe, with the European patent being validated in France, Germany, Italy, Netherlands, Spain, Switzerland/Lichtenstein, and United Kingdom. The Company also has patent applications pending in the United States and in multiple countries. The Company has six allowed trademarks in the United States and two pending applications. Globally, the Company has two European registered trademarks, two United Kingdom trademarks, two pending in Canada, and one allowed and one pending in Japan. Improvements in the design and efficiency of the CellMist™ System including a closed, automated cell isolation device and the SkinGun™ spray device are in development with StemCell Systems (Berlin, Germany), the Company’s R&D innovation partner. The Company is adapting its core technologies for possible use in other clinical indications. The Company is also developing the cell isolation and spray gun devices as stand-alone 510(k)-cleared products for isolation of cells from other tissues and spraying other solutions of medical importance. The Company does not have any commercialized products. The Company's activities have consisted principally of performing research and development activities and raising capital to support such activities. The Company has enlisted the assistance of several Contract Manufacturing Organizations (CMO) to manufacture clinical supplies including components of the CellMist System™ and the electronic SkinGun™ spray devices in compliance with FDA’s guidance for current Good Manufacturing Practices (cGMP) and Contract Research Organizations (CRO) to test and validate the Company’s products and processes and to conduct clinical trials that evaluate initially the safety and feasibility of an autologous skin cell therapy using the Company’s products to facilitate burn wound healing. These development activities are subject to significant risks and uncertainties, including possible failure of preclinical and clinical testing. The Company has not generated any revenue and has sustained recurring losses and negative cash flows from operations since inception. The Company expects to incur losses as it continues development of its products and technologies and expects that it will need to raise additional capital through partnerships or the sale of its securities to accomplish its business plan. Failing to secure such additional funding before achieving sustainable revenue and profit from operations poses a significant risk. The Company's ability to fund the development of its cellular therapies depends on the amount and timing of cash receipts from future financing activities. There can be no assurance as to the availability or terms upon which such financing and capital might be available.

Basis of Presentation The accompanying unaudited interim consolidated financial statements of RenovaCare, Inc. and Subsidiary (the “Company”) as of June 30, 2021, and for the three and six months ended June 30, 2021 and 2020 have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”) for complete financial statements. These Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2020 included in our Annual Report on Form 10-K filed with the SEC on March 31, 2021. The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Consolidated Financial Statements and accompanying disclosures. Actual results may differ from those estimates. The accompanying unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements and include all adjustments (including normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s consolidated financial position as of June 30, 2021, results of operations and stockholders’ equity for the three and six months ended June 30, 2021 and 2020, and cash flows for the six months ended June 30, 2021 and 2020. The Company did not record an income tax provision during the periods presented due to net taxable losses. The results of operations for any interim period are not necessarily indicative of the results of operations for the entire year.

Liquidity As of June 30, 2021, the Company had $4,342,978 of cash on hand and cash equivalents, and working capital of $4,592,838. As a result, the Company believes it currently has sufficient cash to meet its funding requirements over the next twelve months following the issuance of this Quarterly Report on Form 10-Q. However, the Company has experienced and continues to experience negative cash flows from operations, as well as an ongoing requirement for substantial additional capital investment. The Company expects that it may need to raise additional capital to accomplish its business plan over the next several years. There can be no assurance as to the availability or terms upon which such financing and capital might be available. See “Overview of Operations” above. Additionally, there is uncertainty relating to the full impact of the COVID-19 pandemic on the Company’s operations and capital requirements. Should financing when needed be unavailable or prohibitively expensive or the COVID-19 pandemic continue, it may adversely affect the Company’s ability to (i) retain employees and consultants; (ii) obtain additional financing on terms acceptable to the Company, if at all; (iii) delay regulatory submissions and approvals; (iv) delay, limit or preclude the Company from the operation of clinical study sites and testing laboratories; (v) delay, limit or preclude the Company from achieving technology or product development goals, milestones, or objectives; and (vi) preclude or delay entry into joint venture or partnership arrangements. The occurrence of any one or more of such events may affect the Company’s ability to continue on its pathway to commercialization of its technology or products.

4342978

4592838

Recent Accounting Standards Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative non-governmental US GAAP as found in the Financial Accounting Standards Board's Accounting Standards Codification. The Company reviews new accounting standards as issued. Although some of these accounting standards issued or effective after the end of the Company’s previous fiscal year may be applicable, the Company has not identified any standards that the Company believes merit further discussion other than as discussed above. The Company believes that none of the new standards will have a significant impact on the financial statements.

Earnings (Loss) Per Share The Company presents both basic and diluted earnings per share ("EPS") amounts. Basic EPS is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period presented. Diluted EPS amounts are based upon the weighted average number of common and common equivalent shares outstanding during the period presented. The Company has not included the effects of warrants, stock options and convertible debt on net loss per share because to do so would be antidilutive. Following is the computation of basic and diluted net loss per share for the three and six months ended June 30, 2021 and 2020: <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z4USrGhP7ih8" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization, Overview of Operations, Basis of Presentation, Liquidity, Recent Accounting Standards and Earnings (Loss) Per Share (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt">Summary of computation of basic and diluted net loss per share</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_493_20210401__20210630_zAPyomCNYFU5" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49D_20200401__20200630_zO2DCxx4gTT2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_497_20210101__20210630_zVk6MJXwbCud" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_491_20200101__20200630_zi779N49HGn2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">June 30,</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">June 30,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2020</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2020</td></tr> <tr id="xdx_40A_eus-gaap--EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Basic and Diluted EPS Computation</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--NumeratorAbstract_i01B" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Numerator:</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--NetIncomeLoss_i02_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-size: 10pt; text-align: left; padding-left: 10pt">Loss available to common stockholders'</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(911,961</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(3,011,593</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(1,429,203</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(4,186,346</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_404_ecustom--DenominatorAbstract_i01B" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Denominator:</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i02_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 10pt">Weighted average number of common shares outstanding</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">87,352,364</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">87,352,364</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">87,352,364</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">87,352,364</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--EarningsPerShareBasicAndDiluted_i02_pdd" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted EPS</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.01</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.03</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.02</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.05</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--EarningsPerShareDilutedOtherDisclosuresAbstract_iB" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock options</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockCompensationPlanMember_znb8cSuCOer" style="font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">3,089,999</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockCompensationPlanMember_z1vioCGA8eT7" style="font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">4,788,071</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockCompensationPlanMember_z64HAwAoMBKk" style="font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">3,089,999</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockCompensationPlanMember_pdd" style="font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">4,788,071</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 10pt">Warrants</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_ziQrNI6JQZme" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">12,296,912</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zLAzCFCcfG52" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">12,296,912</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zZoaIJjAwQd6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">12,296,912</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">12,296,912</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total shares not included in the computation of diluted losses per share</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20210630_zjet6o00p0Lj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">15,386,911</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20200630_z9hhVogNm4u3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">17,084,983</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">15,386,911</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">17,084,983</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_z4USrGhP7ih8" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Organization, Overview of Operations, Basis of Presentation, Liquidity, Recent Accounting Standards and Earnings (Loss) Per Share (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt">Summary of computation of basic and diluted net loss per share</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_493_20210401__20210630_zAPyomCNYFU5" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_49D_20200401__20200630_zO2DCxx4gTT2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_497_20210101__20210630_zVk6MJXwbCud" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" id="xdx_491_20200101__20200630_zi779N49HGn2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="7" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">June 30,</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">June 30,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2020</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2020</td></tr> <tr id="xdx_40A_eus-gaap--EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Basic and Diluted EPS Computation</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--NumeratorAbstract_i01B" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Numerator:</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--NetIncomeLoss_i02_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-size: 10pt; text-align: left; padding-left: 10pt">Loss available to common stockholders'</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(911,961</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(3,011,593</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(1,429,203</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 10%; font-size: 10pt; text-align: right">(4,186,346</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_404_ecustom--DenominatorAbstract_i01B" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Denominator:</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i02_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 10pt">Weighted average number of common shares outstanding</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">87,352,364</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">87,352,364</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">87,352,364</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">87,352,364</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--EarningsPerShareBasicAndDiluted_i02_pdd" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Basic and diluted EPS</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.01</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.03</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.02</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.05</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--EarningsPerShareDilutedOtherDisclosuresAbstract_iB" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 10pt">Stock options</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockCompensationPlanMember_znb8cSuCOer" style="font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">3,089,999</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockCompensationPlanMember_z1vioCGA8eT7" style="font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">4,788,071</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockCompensationPlanMember_z64HAwAoMBKk" style="font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">3,089,999</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockCompensationPlanMember_pdd" style="font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">4,788,071</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 10pt">Warrants</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_ziQrNI6JQZme" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">12,296,912</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zLAzCFCcfG52" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">12,296,912</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zZoaIJjAwQd6" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">12,296,912</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">12,296,912</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total shares not included in the computation of diluted losses per share</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210401__20210630_zjet6o00p0Lj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">15,386,911</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200401__20200630_z9hhVogNm4u3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">17,084,983</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">15,386,911</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total shares not included in the computation of diluted losses per share">17,084,983</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table>

-911961

-3011593

-1429203

-4186346

87352364

-0.01

-0.03

-0.02

-0.05

3089999

4788071

3089999

4788071

12296912

15386911

17084983

15386911

17084983

Note 2. Prepaid Expenses Prepaid expenses consist of the following: <table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zFLlLdx2HZM4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid Expenses (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt">Prepaid Expenses</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" id="xdx_497_20210630" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" id="xdx_494_20201231" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">June 30,</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">December 31,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2020</td></tr> <tr id="xdx_409_eus-gaap--PrepaidInsurance_iI_pp0p0_maPECzHqi_zC3r8K0Q4LRa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-size: 10pt; text-align: left">Prepaid insurance</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">-</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">54,180</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--PrepaidStockOptionsForServices_iI_pp0p0_maPECzHqi_zTzG6BPcvdJi" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Prepaid stock options for services</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">87,001</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">86,999</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--PrepaidProfessionalFees_iI_pp0p0_maPECzHqi_zDgXWFIghTD4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Prepaid professional fees</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">65,000</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">65,000</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--PrepaidResearchAndDevelopmentExpense_iI_pp0p0_maPECzHqi_zQQT1Lghw003" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Prepaid research and development expense</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">296,196</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">289,746</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPECzHqi_zobuJGKeqk8l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other prepaid costs</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">18,271</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">70,350</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PrepaidExpenseCurrent_iTI_pp0p0_mtPECzHqi_zBaEnMsp3Dce" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">466,468</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">566,275</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_88E_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zFLlLdx2HZM4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid Expenses (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt">Prepaid Expenses</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" id="xdx_497_20210630" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" id="xdx_494_20201231" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">June 30,</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">December 31,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2020</td></tr> <tr id="xdx_409_eus-gaap--PrepaidInsurance_iI_pp0p0_maPECzHqi_zC3r8K0Q4LRa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-size: 10pt; text-align: left">Prepaid insurance</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">-</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">54,180</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--PrepaidStockOptionsForServices_iI_pp0p0_maPECzHqi_zTzG6BPcvdJi" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Prepaid stock options for services</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">87,001</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">86,999</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--PrepaidProfessionalFees_iI_pp0p0_maPECzHqi_zDgXWFIghTD4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Prepaid professional fees</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">65,000</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">65,000</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--PrepaidResearchAndDevelopmentExpense_iI_pp0p0_maPECzHqi_zQQT1Lghw003" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Prepaid research and development expense</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">296,196</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">289,746</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPECzHqi_zobuJGKeqk8l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Other prepaid costs</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">18,271</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">70,350</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PrepaidExpenseCurrent_iTI_pp0p0_mtPECzHqi_zBaEnMsp3Dce" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total prepaid expenses</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">466,468</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">566,275</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table>

54180

87001 86999 65000 65000 296196 289746

18271

70350

466468

566275

Note 3. Equity 2013 Long-Term Incentive Plan On June 20, 2013, the Company’s Board of Directors (the “Board”) adopted the 2013 Long-Term Incentive Plan (the “2013 Plan”) and on November 15, 2013, a stockholder owning a majority of the Company’s issued and outstanding stock approved adoption to the 2013 Plan. Pursuant to the terms of the 2013 Plan, an aggregate of 20,000,000 shares of the Company’s common stock have been reserved for issuance to the Company’s officers, directors, employees and consultants in order to attract and hire key technical personnel and management. Options granted to employees under the 2013 Plan, including directors and officers who are employees, may be incentive stock options or non-qualified stock options; options granted to others under the 2013 Plan are limited to non-qualified stock options. As of June 30, 2021, there were 16,668,266 shares available for future grants. The 2013 Plan is administered by the Board or a committee designated by the Board. Subject to the provisions of the 2013 Plan, the Board has the authority to determine the officers, employees and consultants to whom options will be granted, the number of shares covered by each option, vesting rights and the terms and conditions of each option that is granted to them; however, no person may be granted options to purchase more than 2,000,000 shares in any one fiscal year under the 2013 Plan, and the aggregate fair market value (determined at the time the option is granted) of the shares with respect to which incentive stock options are exercisable for the first time by an optionee during any calendar year cannot exceed $100,000. Options granted pursuant to the 2013 Plan are exercisable no later than ten years after the date of grant. The exercise price per share of common stock for options granted under the 2013 Plan is the fair market value of the Company's common stock on the date of grant, using the closing price of the Company's common stock on the last trading day prior to the date of grant, except for incentive stock options granted to a holder of ten percent or more of the Company's common stock, for whom the exercise price per share will not be less than 110% of the fair market value. No option can be granted under the 2013 Plan after June 20, 2023. Common Stock At June 30, 2021, the Company had 500,000,000 authorized shares of common stock with a par value of $0.00001 per share and 87,352,364 shares of common stock outstanding. During the three and six months ended June 30, 2021 and 2020, the Company did not have any common stock transactions. Warrants The Company has issued warrants to purchase common stock at various exercise prices in connection with loan agreements and private placements. The following table summarizes information about warrants outstanding at June 30, 2021 and December 31, 2020: <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zC1KsTTAmY92" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Summary of warrants outstanding</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Shares of Common Stock Issuable from Warrants Outstanding as of</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">Weighted</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">June 30,</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">December 31,</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Average</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Description</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2020</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Exercise Price</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Expiration</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt; text-align: left">Series E</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEMember_pdd" style="width: 12%; font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">584,416</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEMember_pdd" style="width: 12%; font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">584,416</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEMember_pdd" style="width: 12%; font-size: 10pt; text-align: right" title="Weighted Average Exercise Price">1.54</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 14%; font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEMember_zi8PQpPM0Wp1" style="font: 10pt Times New Roman, Times, Serif">September 9, 2021</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Series F</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember_pdd" style="font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">7,246</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember_pdd" style="font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">7,246</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember_pdd" style="font-size: 10pt; text-align: right" title="Weighted Average Exercise Price">3.45</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember__srt--RangeAxis__srt--MinimumMember_ztcFCxAq997c" style="font: 10pt Times New Roman, Times, Serif">February 23, 2022 & <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember__srt--RangeAxis__srt--MaximumMember_zq5U5jOCaKNa">March 9, 2022</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Series G</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember_pdd" style="font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">460,250</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember_pdd" style="font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">460,250</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember_pdd" style="font-size: 10pt; text-align: right" title="Weighted Average Exercise Price">2.68</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember_ztN90QzGFa7g" style="font: 10pt Times New Roman, Times, Serif">July 21, 2022</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Series H</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember_pdd" style="font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">910,000</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember_pdd" style="font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">910,000</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember_pdd" style="font-size: 10pt; text-align: right" title="Weighted Average Exercise Price">2.75</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember_zAcTJlxfnjqb" style="font: 10pt Times New Roman, Times, Serif">October 16, 2022</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Series I</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">10,335,000</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">10,335,000</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">$</td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember_pdd" style="padding-bottom: 1pt; font-size: 10pt; text-align: right" title="Weighted Average Exercise Price">2.00</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: right; padding-bottom: 1pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember_zWoaQQQPllrf" style="font: 10pt Times New Roman, Times, Serif">November 26, 2025</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.5pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20210630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">12,296,912</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">12,296,912</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td></tr> </table> Stock Options The following table summarizes stock option activity for the six months ended June 30, 2021: <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zkdyUzGvzzcf" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details 1)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">Summary of stock option activity</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Number of Options</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted Average Exercise Price ($)</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (years)</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Aggregate Intrinsic Value ($)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt">Outstanding at December 31, 2020</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20210630_z5RDPYR1GcBg" style="width: 12%; font-size: 10pt; text-align: right" title="Options outstanding - beginning balance">5,895,570</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630_z5bOcaqHI27f" style="width: 12%; font-size: 10pt; text-align: right" title="Weighted Average Exercise Price, Options outstanding - beginning balance">2.45</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zdZJWRJtjP1b" title="Options outstanding">5.14</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20210101__20210630_zOeFdKrW3Mtj" style="width: 12%; font-size: 10pt; text-align: right" title="Aggregate intrinsic value, Options outstanding - beginning balance">3,376,267</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt">Forfeited</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20210630_zCNRjW4gMG4a" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Options forfeited">(2,805,571</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630_zZfT9ptw4eb" style="padding-bottom: 1pt; font-size: 10pt; text-align: right" title="Weighted Average Exercise Price, Options forfeited">2.74</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt">Outstanding at June 30, 2021</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210630_z7uGbcQ8Z7ji" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Options oustanding - ending balance">3,089,999</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630_zMs4RjCIS9S" style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right" title="Weighted Average Exercise Price, Options outstanding - ending balance">2.18</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630_zA4VGS51nWkk" title="Options outstanding">4.96</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20210101__20210630_zXfwp38Mzc0f" style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right" title="Aggregate intrinsic value, Options oustanding - ending balance">4,177,775</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Vested and exercisable at June 30, 2021</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210101__20210630_zp1VrQmwSZpg" style="font-size: 10pt; text-align: right" title="Options Vested and Exercisable">2,427,499</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20210101__20210630_zOt6UddH4F77" style="font-size: 10pt; text-align: right" title="Weighted Average Exercise Price, Options Vested and Exercisable">1.90</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630_zMmIfOC3cP4j" title="Options Vested and Exercisable">4.93</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20210101__20210630_zNd5SQKS8HV7" style="font-size: 10pt; text-align: right" title="Aggregate intrinsic value, Options Vested and Exercisable">3,972,400</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected term of the stock options. The ranges of assumptions used in the Black-Scholes Model during the six months ended June 30, 2020 is set forth in the table below: <table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfAssumptionsForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock_zSncXY5TpV84" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details 2)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt">Summary of assumption of stock option activity</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">June 30, 2020</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; width: 85%">Risk-free interest rate</td> <td style="font-size: 10pt; width: 1%"> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200101__20200630__srt--RangeAxis__srt--MinimumMember_z9rbMG0xGMYb" style="font-size: 10pt; text-align: center; width: 5%" title="Risk-free interest rate">0.034%</td> <td style="font-size: 10pt; text-align: center; width: 4%">-</td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200101__20200630__srt--RangeAxis__srt--MaximumMember_zNaCqqjeKv4i" style="font-size: 10pt; text-align: center; width: 5%" title="Risk-free interest rate">1.67%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected term in years</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200630__srt--RangeAxis__srt--MinimumMember_z4m2GkgjfVjf" title="Expected life in years">3.25</td> <td style="font-size: 10pt; text-align: center">–</td> <td style="font-size: 10pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200630__srt--RangeAxis__srt--MaximumMember_zsxqUBPhyPlc" title="Expected life in years">4.98</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Weighted Avg. Expected Volatility</td> <td style="font-size: 10pt"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200101__20200630__srt--RangeAxis__srt--MinimumMember_zqi67C7UDmZc" style="font-size: 10pt; text-align: center" title="Expected Volatility">105.71%</td> <td style="font-size: 10pt; text-align: center">–</td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200101__20200630__srt--RangeAxis__srt--MaximumMember_zufcoDYN5fhb" style="font-size: 10pt; text-align: center" title="Expected Volatility">106.88%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected dividend yield</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20200101__20200630_zGQFNRFH9k3d" style="font-size: 10pt; text-align: center" title="Expected dividend yield">0%</td> <td style="font-size: 10pt; text-align: center"> </td></tr> </table> The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term. Estimated volatility is a measure of the amount by which the stock price is expected to fluctuate each year during the term of an award. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. The average expected life is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Future stock-based compensation may significantly differ based on changes in the fair value of our Common Stock and our estimates of expected volatility and the other relevant assumptions. The following table sets forth the share-based compensation cost resulting from stock option grants, including those previously granted and vesting over time, that were recorded in the Company’s Statements of Operations for the three and six months ended June 30, 2021 and 2020: <table cellpadding="0" cellspacing="0" id="xdx_88B_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zeYNSUw2hNy2" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details 3)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Summary of consolidated statement of operations</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended June 30</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2020</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2020</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt; text-align: left">Research and development</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="width: 12%; font-size: 10pt; text-align: right" title="Total">228,625</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="width: 12%; font-size: 10pt; text-align: right" title="Total">631,876</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="width: 12%; font-size: 10pt; text-align: right" title="Total">507,438</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_pp0p0_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgXMRr4yf7Lc" style="width: 12%; font-size: 10pt; text-align: right" title="Total">631,876</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total">(29,026</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total">954,646</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total">(1,182,601</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total">1,420,409</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20210401__20210630_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total">(199,599</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20200401__20200630_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total">1,586,522</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20210101__20210630_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total">(675,163</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20200101__20200630_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total">2,052,285</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> Three and Six Months Ended June 30, 2021 During the first half of 2021, certain individuals resigned from the Company resulting in the forfeiture and cancellation of 2,805,571 options. Compensation expense was recorded on some of these options prior to their full vesting. As a result, during the three and six months ended June 30, 2021, the Company recognized $66,130 and $1,248,575, respectively, of reversals of the prior recognized compensation expense related to the cancelled options. During the three and six months ended June 30, 2021, the expense recognized for options still in their vesting period totaled $265,726 and $639,541, respectively.

20000000

16668266

500000000

0.00001

87352364

<table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zC1KsTTAmY92" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Summary of warrants outstanding</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Shares of Common Stock Issuable from Warrants Outstanding as of</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: center">Weighted</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">June 30,</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">December 31,</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center">Average</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Description</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2020</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Exercise Price</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Expiration</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt; text-align: left">Series E</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEMember_pdd" style="width: 12%; font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">584,416</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEMember_pdd" style="width: 12%; font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">584,416</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEMember_pdd" style="width: 12%; font-size: 10pt; text-align: right" title="Weighted Average Exercise Price">1.54</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 14%; font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesEMember_zi8PQpPM0Wp1" style="font: 10pt Times New Roman, Times, Serif">September 9, 2021</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Series F</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember_pdd" style="font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">7,246</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember_pdd" style="font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">7,246</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember_pdd" style="font-size: 10pt; text-align: right" title="Weighted Average Exercise Price">3.45</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember__srt--RangeAxis__srt--MinimumMember_ztcFCxAq997c" style="font: 10pt Times New Roman, Times, Serif">February 23, 2022 & <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesFMember__srt--RangeAxis__srt--MaximumMember_zq5U5jOCaKNa">March 9, 2022</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Series G</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember_pdd" style="font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">460,250</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember_pdd" style="font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">460,250</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember_pdd" style="font-size: 10pt; text-align: right" title="Weighted Average Exercise Price">2.68</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGMember_ztN90QzGFa7g" style="font: 10pt Times New Roman, Times, Serif">July 21, 2022</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Series H</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember_pdd" style="font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">910,000</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember_pdd" style="font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">910,000</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember_pdd" style="font-size: 10pt; text-align: right" title="Weighted Average Exercise Price">2.75</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesHMember_zAcTJlxfnjqb" style="font: 10pt Times New Roman, Times, Serif">October 16, 2022</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Series I</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">10,335,000</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20201231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember_pdd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">10,335,000</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">$</td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember_pdd" style="padding-bottom: 1pt; font-size: 10pt; text-align: right" title="Weighted Average Exercise Price">2.00</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: right; padding-bottom: 1pt"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20210101__20210630__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesIMember_zWoaQQQPllrf" style="font: 10pt Times New Roman, Times, Serif">November 26, 2025</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 2.5pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20210630__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">12,296,912</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_c20201231__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Shares of Common Stock Issuable from Warrants Outstanding">12,296,912</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td></tr> </table>

584416

1.54

2021-09-09

7246

3.45

2022-02-23

2022-03-09

460250

2.68

2022-07-21

910000

2.75

2022-10-16

10335000

2.00

2025-11-26

12296912

<table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zkdyUzGvzzcf" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details 1)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">Summary of stock option activity</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Number of Options</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted Average Exercise Price ($)</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (years)</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Aggregate Intrinsic Value ($)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt">Outstanding at December 31, 2020</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20210630_z5RDPYR1GcBg" style="width: 12%; font-size: 10pt; text-align: right" title="Options outstanding - beginning balance">5,895,570</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630_z5bOcaqHI27f" style="width: 12%; font-size: 10pt; text-align: right" title="Weighted Average Exercise Price, Options outstanding - beginning balance">2.45</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20200101__20201231_zdZJWRJtjP1b" title="Options outstanding">5.14</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20210101__20210630_zOeFdKrW3Mtj" style="width: 12%; font-size: 10pt; text-align: right" title="Aggregate intrinsic value, Options outstanding - beginning balance">3,376,267</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt">Forfeited</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20210630_zCNRjW4gMG4a" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Options forfeited">(2,805,571</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630_zZfT9ptw4eb" style="padding-bottom: 1pt; font-size: 10pt; text-align: right" title="Weighted Average Exercise Price, Options forfeited">2.74</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt">Outstanding at June 30, 2021</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210630_z7uGbcQ8Z7ji" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Options oustanding - ending balance">3,089,999</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630_zMs4RjCIS9S" style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right" title="Weighted Average Exercise Price, Options outstanding - ending balance">2.18</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630_zA4VGS51nWkk" title="Options outstanding">4.96</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20210101__20210630_zXfwp38Mzc0f" style="padding-bottom: 2.5pt; font-size: 10pt; text-align: right" title="Aggregate intrinsic value, Options oustanding - ending balance">4,177,775</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Vested and exercisable at June 30, 2021</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210101__20210630_zp1VrQmwSZpg" style="font-size: 10pt; text-align: right" title="Options Vested and Exercisable">2,427,499</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_c20210101__20210630_zOt6UddH4F77" style="font-size: 10pt; text-align: right" title="Weighted Average Exercise Price, Options Vested and Exercisable">1.90</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630_zMmIfOC3cP4j" title="Options Vested and Exercisable">4.93</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20210101__20210630_zNd5SQKS8HV7" style="font-size: 10pt; text-align: right" title="Aggregate intrinsic value, Options Vested and Exercisable">3,972,400</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table>

5895570

2.45

P5Y1M20D

3376267

2805571

2.74

3089999

2.18

P4Y11M15D

4177775

2427499

1.90

P4Y11M4D

3972400

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfAssumptionsForFairValueOnSecuritizationDateOfInterestsContinuedToBeHeldByTransferorServicingAssetsOrServicingLiabilitiesTextBlock_zSncXY5TpV84" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details 2)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt">Summary of assumption of stock option activity</td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">June 30, 2020</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; width: 85%">Risk-free interest rate</td> <td style="font-size: 10pt; width: 1%"> </td> <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200101__20200630__srt--RangeAxis__srt--MinimumMember_z9rbMG0xGMYb" style="font-size: 10pt; text-align: center; width: 5%" title="Risk-free interest rate">0.034%</td> <td style="font-size: 10pt; text-align: center; width: 4%">-</td> <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20200101__20200630__srt--RangeAxis__srt--MaximumMember_zNaCqqjeKv4i" style="font-size: 10pt; text-align: center; width: 5%" title="Risk-free interest rate">1.67%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected term in years</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200630__srt--RangeAxis__srt--MinimumMember_z4m2GkgjfVjf" title="Expected life in years">3.25</td> <td style="font-size: 10pt; text-align: center">–</td> <td style="font-size: 10pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200630__srt--RangeAxis__srt--MaximumMember_zsxqUBPhyPlc" title="Expected life in years">4.98</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Weighted Avg. Expected Volatility</td> <td style="font-size: 10pt"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200101__20200630__srt--RangeAxis__srt--MinimumMember_zqi67C7UDmZc" style="font-size: 10pt; text-align: center" title="Expected Volatility">105.71%</td> <td style="font-size: 10pt; text-align: center">–</td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20200101__20200630__srt--RangeAxis__srt--MaximumMember_zufcoDYN5fhb" style="font-size: 10pt; text-align: center" title="Expected Volatility">106.88%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Expected dividend yield</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: center"> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20200101__20200630_zGQFNRFH9k3d" style="font-size: 10pt; text-align: center" title="Expected dividend yield">0%</td> <td style="font-size: 10pt; text-align: center"> </td></tr> </table> The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term. Estimated volatility is a measure of the amount by which the stock price is expected to fluctuate each year during the term of an award. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. The average expected life is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Future stock-based compensation may significantly differ based on changes in the fair value of our Common Stock and our estimates of expected volatility and the other relevant assumptions.

0.00034

0.0167

P3Y3M

P4Y11M23D

1.0571

1.0688

<table cellpadding="0" cellspacing="0" id="xdx_88B_esrt--ScheduleOfCondensedIncomeStatementTableTextBlock_zeYNSUw2hNy2" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity (Details 3)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Summary of consolidated statement of operations</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Six Months Ended June 30</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2020</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2021</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2020</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt; text-align: left">Research and development</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="width: 12%; font-size: 10pt; text-align: right" title="Total">228,625</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="width: 12%; font-size: 10pt; text-align: right" title="Total">631,876</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="width: 12%; font-size: 10pt; text-align: right" title="Total">507,438</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_pp0p0_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgXMRr4yf7Lc" style="width: 12%; font-size: 10pt; text-align: right" title="Total">631,876</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total">(29,026</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total">954,646</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total">(1,182,601</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Total">1,420,409</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20210401__20210630_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total">(199,599</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20200401__20200630_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total">1,586,522</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20210101__20210630_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total">(675,163</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_c20200101__20200630_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total">2,052,285</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table>

228625

631876

507438

631876

-29026

954646

-1182601

1420409

-199599

1586522

-675163

2052285

2805571

66130 1248575

265726

639541

Note 4. Leases In February 2020, the Company entered into a two-year lease for office premises located at 4 Becker Farm Road, Suite 105, Roseland, New Jersey. Monthly base rent in year one of the lease is $4,356; and $4,459 in year 2 of the lease. The term (and payment of the monthly rent) commenced upon completion of the landlord’s work on August 1, 2020. The Company’s existing Lease is not subject to any restrictions or covenants which preclude its ability to pay dividends, obtain financing, or enter into additional Lease’s. As of June 30, 2021, the Company has not entered into any leases which have not yet commenced which would entitle the Company to significant rights or create additional obligations. The Company does not have any finance leases. Supplemental lease information as of June 30, 2021: <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zRwTxY3KZJNg" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: justify">Schedule of supplemental lease information</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: justify"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of June 30, 2021</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of December 31, 2020</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: justify"> </td> <td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-size: 10pt; text-align: justify">Operating lease right-of-use asset</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_c20210630_pp0p0" style="width: 12%; font-size: 10pt; text-align: right" title="Operating lease right-of-use asset">53,492</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td id="xdx_989_eus-gaap--OperatingLeaseRightOfUseAsset_c20201231_pp0p0" style="width: 12%; font-size: 10pt; text-align: right" title="Operating lease right-of-use asset">79,462</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify">Current maturities of operating lease</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td> <td id="xdx_98F_eus-gaap--OperatingLeaseLiabilityCurrent_c20210630_pp0p0" style="font-size: 10pt; text-align: right" title="Current maturities of operating lease">51,132</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td> <td id="xdx_98A_eus-gaap--OperatingLeaseLiabilityCurrent_c20201231_pp0p0" style="font-size: 10pt; text-align: right" title="Current maturities of operating lease">51,125</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Non-current operating lease</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20210630_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-current operating lease">4,433</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_985_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20201231_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-current operating lease">28,607</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Total operating lease liabilities</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td id="xdx_986_eus-gaap--OperatingLeaseLiability_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total operating lease liabilities">55,565</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td id="xdx_985_eus-gaap--OperatingLeaseLiability_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total operating lease liabilities">79,732</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify">Weighted Average remaining lease term (in years):</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">1.09</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">1.6</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Discount rate:</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_981_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20210630_zRynPi2uTcz4" style="font-size: 10pt; text-align: right" title="Discount rate">7.0</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_98C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20201231_zevS6WLxndvk" style="font-size: 10pt; text-align: right" title="Discount rate">7.0</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Right-of-use asset obtained in exchange for lease obligation</td> <td style="font-size: 10pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td> <td id="xdx_98D_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20210101__20210630_pp0p0" style="font-size: 10pt; text-align: right" title="Right-of-use asset obtained in exchange for lease obligation">98,402</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> Supplemental cash flow information for the six months ended June 30, 2021: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; font-size: 10pt; text-align: left">Cash paid for amount included in the measurement of lease liabilities for operating lease</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td id="xdx_490_20210101_20210630" style="width: 12%; font-size: 10pt; text-align: right">26,136</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> </table> The Company leases office space under a non-cancellable operating lease expiring in 2022. Future lease payments included in the measurement of lease liabilities on the balance sheet at June 30, 2021 for future periods are as follows: <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zvNU2sRUtXHa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="display: none; font-size: 10pt; text-align: left; padding-bottom: 1pt">Schedule of future lease payments</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_499_20210630_zMy2XxjEkisf" style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left; white-space: nowrap; font-size: 10pt">Years ending December 31, 2021,</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueCurrent_iI_pp0p0_maOLFMPzBNj_zsVEL6Mv3VRd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 85%; font-size: 10pt">2021 (Remaining)</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">26,652</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_pp0p0_maOLFMPzBNj_zMKo4Uomb8Va" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">2022</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">31,213</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iTI_pp0p0_mtOLFMPzBNj_zXYNFb8IBE7h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Total future minimum lease payments</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">57,864</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--ImputedInterest_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less imputed interest</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,299</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; font-size: 10pt; padding-bottom: 2.5pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">55,565</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table>

4356 4459

P2Y

<table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zRwTxY3KZJNg" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: justify">Schedule of supplemental lease information</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: justify"> </td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of June 30, 2021</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of December 31, 2020</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: justify"> </td> <td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right"> </td> <td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; font-size: 10pt; text-align: justify">Operating lease right-of-use asset</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td id="xdx_983_eus-gaap--OperatingLeaseRightOfUseAsset_c20210630_pp0p0" style="width: 12%; font-size: 10pt; text-align: right" title="Operating lease right-of-use asset">53,492</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td id="xdx_989_eus-gaap--OperatingLeaseRightOfUseAsset_c20201231_pp0p0" style="width: 12%; font-size: 10pt; text-align: right" title="Operating lease right-of-use asset">79,462</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify">Current maturities of operating lease</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td> <td id="xdx_98F_eus-gaap--OperatingLeaseLiabilityCurrent_c20210630_pp0p0" style="font-size: 10pt; text-align: right" title="Current maturities of operating lease">51,132</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td> <td id="xdx_98A_eus-gaap--OperatingLeaseLiabilityCurrent_c20201231_pp0p0" style="font-size: 10pt; text-align: right" title="Current maturities of operating lease">51,125</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Non-current operating lease</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_98B_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20210630_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-current operating lease">4,433</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td id="xdx_985_eus-gaap--OperatingLeaseLiabilityNoncurrent_c20201231_pp0p0" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Non-current operating lease">28,607</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Total operating lease liabilities</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td id="xdx_986_eus-gaap--OperatingLeaseLiability_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total operating lease liabilities">55,565</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td id="xdx_985_eus-gaap--OperatingLeaseLiability_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Total operating lease liabilities">79,732</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: justify">Weighted Average remaining lease term (in years):</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">1.09</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">1.6</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: justify">Discount rate:</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_981_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20210630_zRynPi2uTcz4" style="font-size: 10pt; text-align: right" title="Discount rate">7.0</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_98C_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20201231_zevS6WLxndvk" style="font-size: 10pt; text-align: right" title="Discount rate">7.0</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Right-of-use asset obtained in exchange for lease obligation</td> <td style="font-size: 10pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap; text-align: left"> </td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td> <td id="xdx_98D_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20210101__20210630_pp0p0" style="font-size: 10pt; text-align: right" title="Right-of-use asset obtained in exchange for lease obligation">98,402</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> Supplemental cash flow information for the six months ended June 30, 2021: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%; font-size: 10pt; text-align: left">Cash paid for amount included in the measurement of lease liabilities for operating lease</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td id="xdx_490_20210101_20210630" style="width: 12%; font-size: 10pt; text-align: right">26,136</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> </table>

53492

79462

51132

51125

4433

28607

55565

79732

P1Y1M2D

P1Y7M6D

0.070

98402

<table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_zvNU2sRUtXHa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="display: none; font-size: 10pt; text-align: left; padding-bottom: 1pt">Schedule of future lease payments</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td id="xdx_499_20210630_zMy2XxjEkisf" style="font-size: 10pt; text-align: right"> </td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; text-align: left; white-space: nowrap; font-size: 10pt">Years ending December 31, 2021,</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt"> </td></tr> <tr id="xdx_407_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueCurrent_iI_pp0p0_maOLFMPzBNj_zsVEL6Mv3VRd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 85%; font-size: 10pt">2021 (Remaining)</td> <td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right">26,652</td> <td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeasesFutureMinimumPaymentsDueInTwoYears_iI_pp0p0_maOLFMPzBNj_zMKo4Uomb8Va" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">2022</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">31,213</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingLeasesFutureMinimumPaymentsDue_iTI_pp0p0_mtOLFMPzBNj_zXYNFb8IBE7h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Total future minimum lease payments</td> <td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td> <td style="font-size: 10pt; text-align: right">57,864</td> <td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--ImputedInterest_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less imputed interest</td> <td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,299</td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; font-size: 10pt; padding-bottom: 2.5pt">Total</td> <td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">55,565</td> <td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table>

26652

31213

57864

-2299

55565

Note 5. Commitments and Contingencies Stem Cell Systems In connection with the Company’s anticipated regulatory filings, the Company has engaged StemCell Systems GmbH (“StemCell Systems”) to provide it with prototypes and related documents under various agreements. On July 1, 2020, the Company and StemCell Systems entered into a Strategic R&D Agreement (the “Strategic Agreement”) having an initial term of three years with successive one-year extensions unless earlier terminated. The Strategic Agreement includes a $27,000 monthly fee to be paid to StemCell Systems along with any additional expenses incurred. The Company, StemCell Systems and certain affiliates of StemCells entered into a Rights of First Refusal and Corporate Opportunities Agreement (the “ROFR Agreement”). Pursuant to the ROFR Agreement, (i) in the event a StemCell Systems stockholder receives an offer from a third party to acquire the StemCell Systems stockholders ownership interest, the Company shall have ten business days to purchase such ownership, and (ii) if during the terms of the Strategic Agreement, any StemCell Systems inventions, with respect to skin, burns and wounds, designs, inventions and among other things, whether or not patentable, copyrightable or otherwise legally protectable are discovered by StemCell Systems, the Company shall have the first option to negotiate mutually agreeable terms for the Company’s acquisition or licensing of the StemCell Systems inventions. Pursuant to these engagements the Company incurred expenses of approximately $128,000 and $122,000 during the three months ended June 30, 2021 and 2020, respectively; and $248,000 and $199,000 during the six months ended June 30, 2021 and 2020, respectively. SEC Complaint On May 28, 2021 the SEC filed a civil complaint naming the Company and Harmel S. Rayat, RenovaCare Chairman as defendants (the “Complaint”). The Complaint charges Mr. Rayat and the Company with violating the antifraud provisions of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and also charges Mr. Rayat with aiding and abetting the Company's violations of those provisions. The complaint also charges the Company with violating the reporting provisions of Exchange Act Section 15(d) and Rules 15d-11 and 12b-20 thereunder. The SEC seeks permanent injunctions and civil penalties against Mr. Rayat and the Company, and officer-and-director and penny stock bars against Mr. Rayat. The Company believes that the claims asserted in the Complaint are without merit and intends to defend this matter vigorously. Most, if not all, of the cost to defend the Company and Mr. Rayat is expected to be covered by insurance. However, because of the inherent uncertainty as to the outcome of this proceeding, the Company is unable, at this time, to estimate the possible impact of the outcome of this matter nor provide assurance that the available insurance coverage will be sufficient to see the Complaint through to resolution. Class Action Complaints On July 16 and July 21, 2021, two purported shareholders of the Company filed putative class actions in the United States District Court for the District of New Jersey against the Company and certain of its current and former executive officers (captioned Gabrielle A. Boller, Individually and On Behalf of All Others Similarly Situated v. RenovaCare, Inc., Harmel Rayat, and Thomas Bold, No. 2:21-cv-13766-SDW-ESK (“Boller”), and Michael Solakian, Individually and On Behalf of All Others Similarly Situated v. RenovaCare, Inc., Harmel Rayat, and Thomas Bold, No. 2:21-cv-13930 (“Solakian”), respectively). The complaints in Boller and Solakian were brought both individually and on behalf of a putative class of the Company’s stockholders, claiming that in connection with the facts and circumstances underlying the allegations in the SEC Complaint, the Company engaged in fraudulent conduct and made false and misleading statements of material fact or omitted to state material facts necessary to make the statements made not misleading. Both Boller and Solakian seek to declare the action to be a class action and monetary damages, including costs and expenses, and award of reasonable attorneys’ fees, expert fees, and other costs, and such other relief as the Court may deem just and proper. The Company believes that the claims asserted in Boller and Solakian and any other Class Actions derived from the SEC Complaint are without merit and intends to defend itself vigorously. Based on the early stages of these legal proceedings, and the inherent uncertainty as to their outcome, at this time, the Company is not able to reasonably estimate a possible range of loss, if any, that may result from the allegations set forth in the complaints filed in the Class Actions.

27000

128000

122000

248000

199000

Note 6. Related Party Transactions During the three and six months ended June 30, 2020, Talia Jevan Properties, Inc. made payments totaling $5,287 and $10,811, respectively, to Stephen Yan-Klassen, former CFO who resigned in 2020, for his salary on behalf of the Company. Talia Jevan Properties, Inc. is a related party of Harmel S. Rayat, Chairman of the Board. On August 1, 2013, the Company entered into a consulting agreement, as amended on May 1, 2016, with Jatinder Bhogal, an individual owning in excess of 5% of the Company’s issued and outstanding shares of common stock, to provide consulting services to the Company through his wholly owned company, Vector Asset Management, Inc. (“VAMI”). Pursuant to the consulting agreement, VAMI assisted the Company with identifying subject matter experts in the medical device and biotechnology industries and assisted the Company with its ongoing research, development and eventual commercialization of its Regeneration Technology. Pursuant to an amendment dated May 1, 2016, the VAMI monthly consulting fee was increased from $5,000 to $6,800. On June 22, 2018, the Company and VAM entered into an Executive Consulting Agreement (the “ECA”) pursuant to which Mr. Bhogal served as the Company’s Chief Operating Officer. The ECA supersedes the prior consulting agreement. Pursuant to the ECA, VAMI received compensation of $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_c20180601__20180622__us-gaap--RelatedPartyTransactionAxis__custom--VectorAssetManagementIncMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif">120,000 <span id="xdx_909_ecustom--PaymentOfCompensationDescription_c20180601__20180622__us-gaap--RelatedPartyTransactionAxis__custom--VectorAssetManagementIncMember" style="font: 10pt Times New Roman, Times, Serif">per year. On July 1, 2020 the Company amended the ECA and paid VAMI $4,000 per month through November 30, 2020 and $200 per month thereafter until May 31, 2021 at which time the ECA as amended expired. For consulting services provided by VAMI, during the three months ended June 30, 2021 and 2020, the Company recognized expenses of $400 and $30,000, respectively; and $1,000 and $60,000 during the six months ended June 30, 2021 and 2020, respectively. Jatinder Bhogal resigned as the Company’s COO effective June 30, 2020.

5287

10811

120000

per year. On July 1, 2020 the Company amended the ECA and paid VAMI $4,000 per month through November 30, 2020 and $200 per month thereafter until May 31, 2021 at which time the ECA as amended expired.

400

30000

1000

60000

Note 7. Subsequent Events Management has reviewed material events subsequent of the period ended June 30, 2021 and prior to the filing of financial statements in accordance with FASB ASC 855 “Subsequent Events”.

XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2021	Aug. 02, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-30156
Entity Registrant Name	RENOVACARE, INC.
Entity Central Index Key	0001016708
Entity Tax Identification Number	98-0384030
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	9375 E. Shea Blvd
Entity Address, Address Line Two	Suite 107-A
Entity Address, City or Town	Scottsdale
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85260
City Area Code	888
Local Phone Number	398-0202
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		87,352,364

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current assets
Cash	$ 4,342,978	$ 7,412,969
Prepaid expenses	466,468	566,275
Total current assets	4,809,446	7,979,244
Equipment, net of accumulated depreciation of $8,308 and $3,584, respectively	33,916	38,640
Intangible assets	152,854	152,854
Security Deposit	7,995	7,995
Right of Use Asset	53,492	79,462
Other Assets	94,247	137,749
Total assets	5,151,950	8,395,944
Current liabilities
Accounts payable and accrued liabilities	165,476	1,237,437
Lease liability - current	51,132	51,125
Total current liabilities	216,608	1,288,562
Lease Liability - long term	4,433	28,607
Total liabilities	221,041	1,317,169
Stockholders' equity
Preferred stock: $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding
Common stock: $0.00001 par value; 500,000,000 shares authorized, 87,352,364 shares issued and outstanding at June 30, 2021 and December 31, 2020	874	874
Additional paid-in capital	36,127,419	36,846,082
Retained deficit	(31,197,384)	(29,768,181)
Total stockholders' equity	4,930,909	7,078,775
Total liabilities and stockholders' equity	$ 5,151,950	$ 8,395,944

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred Stock, Par Value	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value	$ 0.00001	$ 0.00001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares, Issued	87,352,364	87,352,364
Common Stock, Shares, Outstanding	87,352,364	87,352,364

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenue
Operating expenses
Research and development	704,569	1,347,005	1,758,862	1,539,778
General and administrative	400,810	1,697,476	(136,234)	2,733,042
Total operating expenses, net	1,105,379	3,044,481	1,622,628	4,272,820
Loss from operations	(1,105,379)	(3,044,481)	(1,622,628)	(4,272,820)
Other income
Interest income	2,615	32,888	2,622	86,474
Other income	190,803		190,803
Total other income	193,418	32,888	193,425	86,474
Net loss	$ (911,961)	$ (3,011,593)	$ (1,429,203)	$ (4,186,346)
Basic and Diluted Loss per Common Share	$ (0.01)	$ (0.03)	$ (0.02)	$ (0.05)
Weighted average number of common shares outstanding - basic and diluted	87,352,364	87,352,364	87,352,364	87,352,364

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 874	$ 32,378,833	$ (20,219,845)	$ 12,159,862
Shares, Outstanding at beginning at Dec. 31, 2019	87,352,364
Stock based compensation due to common stock purchase options		465,763		465,763
Net loss			(1,174,753)	(1,174,753)
Ending balance, value at Mar. 31, 2020	$ 874	32,844,596	(21,394,598)	11,450,872
Shares, Outstanding at end at Mar. 31, 2020	87,352,364
Stock based compensation due to common stock purchase options		1,586,522		1,586,522
Net loss			(3,011,593)	(3,011,593)
Ending balance, value at Jun. 30, 2020	$ 874	34,431,118	(24,406,191)	10,025,801
Shares, Outstanding at end at Jun. 30, 2020	87,352,364
Beginning balance, value at Dec. 31, 2020	$ 874	36,846,082	(29,768,181)	7,078,775
Shares, Outstanding at beginning at Dec. 31, 2020	87,352,364
Stock based compensation due to common stock purchase options		352,063		352,063
Reversal of stock based compensation due to common stock purchase option cancellations		(1,248,575)		(1,248,575)
Net loss			(517,242)	(517,242)
Ending balance, value at Mar. 31, 2021	$ 874	35,949,570	(30,285,423)	5,665,021
Shares, Outstanding at end at Mar. 31, 2021	87,352,364
Stock based compensation due to common stock purchase options		243,979		243,979
Reversal of stock based compensation due to common stock purchase option cancellations		(66,130)		(66,130)
Net loss			(911,961)	(911,961)
Ending balance, value at Jun. 30, 2021	$ 874	$ 36,127,419	$ (31,197,384)	$ 4,930,909
Shares, Outstanding at end at Jun. 30, 2021	87,352,364

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows used in operating activities
Net loss	$ (1,429,203)	$ (4,186,346)
Adjustments to reconcile net loss to net cash flows used in operating activities
Depreciation expense	4,724
Stock based compensation expense	(675,163)	2,052,285
Amortization of right of use asset	25,970
Changes in operating assets and liabilities:
(Increase) decrease in prepaid expenses and other assets	99,807	(301,685)
Increase (decrease) in accounts payable	(1,071,961)	497,738
Increase (decrease) in accounts payable - related parties		18,823
Increase (decrease) in lease liability	(24,165)
Net cash flows used in operating activities	(3,069,991)	(1,919,185)
Cash flows from investing activity
Decrease (increase) in security deposit		(7,995)
Net cash flows from investing activity		(7,995)
Decrease in cash	(3,069,991)	(1,927,180)
Cash at beginning of period	7,412,969	12,185,248
Cash at end of period	$ 4,342,978	$ 10,258,068

XML 17 R7.htm IDEA: XBRL DOCUMENT

Organization, Overview of Operations, Basis of Presentation, Liquidity, Recent Accounting Standards and Earnings (Loss) Per Share

6 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Organization, Overview of Operations, Basis of Presentation, Liquidity, Recent Accounting Standards and Earnings (Loss) Per Share

Note 1. Organization, Overview of Operations, Basis of Presentation, Liquidity, Recent Accounting Standards and Earnings (Loss) Per Share

Organization

Overview of Operations

Basis of Presentation

Liquidity

Recent Accounting Standards

Earnings (Loss) Per Share

Following is the computation of basic and diluted net loss per share for the three and six months ended June 30, 2021 and 2020:


	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2021			2020			2021			2020
Basic and Diluted EPS Computation
Numerator:
Loss available to common stockholders'	$	(911,961	)	$	(3,011,593	)	$	(1,429,203	)	$	(4,186,346	)
Denominator:
Weighted average number of common shares outstanding		87,352,364			87,352,364			87,352,364			87,352,364
Basic and diluted EPS	$	(0.01	)	$	(0.03	)	$	(0.02	)	$	(0.05	)

The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:
Stock options		3,089,999			4,788,071			3,089,999			4,788,071
Warrants		12,296,912			12,296,912			12,296,912			12,296,912
Total shares not included in the computation of diluted losses per share		15,386,911			17,084,983			15,386,911			17,084,983

XML 18 R8.htm IDEA: XBRL DOCUMENT

Prepaid Expenses

6 Months Ended

Jun. 30, 2021

Prepaid Expenses

Prepaid Expenses

Note 2. Prepaid Expenses

Prepaid expenses consist of the following:

Prepaid Expenses
	June 30,		December 31,
	2021		2020
Prepaid insurance	$	-	$	54,180
Prepaid stock options for services		87,001		86,999
Prepaid professional fees		65,000		65,000
Prepaid research and development expense		296,196		289,746
Other prepaid costs		18,271		70,350
Total prepaid expenses	$	466,468	$	566,275

XML 19 R9.htm IDEA: XBRL DOCUMENT

Equity

6 Months Ended

Jun. 30, 2021

Equity Method Investments and Joint Ventures [Abstract]

Equity

Note 3. Equity

2013 Long-Term Incentive Plan

Common Stock

At June 30, 2021, the Company had 500,000,000 authorized shares of common stock with a par value of $0.00001 per share and 87,352,364 shares of common stock outstanding.

During the three and six months ended June 30, 2021 and 2020, the Company did not have any common stock transactions.

Warrants

Summary of warrants outstanding
	Shares of Common Stock Issuable from Warrants Outstanding as of				Weighted
	June 30,		December 31,		Average
Description	2021		2020		Exercise Price		Expiration
Series E		584,416		584,416	$	1.54	September 9, 2021
Series F		7,246		7,246	$	3.45	February 23, 2022 & March 9, 2022
Series G		460,250		460,250	$	2.68	July 21, 2022
Series H		910,000		910,000	$	2.75	October 16, 2022
Series I		10,335,000		10,335,000	$	2.00	November 26, 2025
Total		12,296,912		12,296,912

Stock Options

The following table summarizes stock option activity for the six months ended June 30, 2021:

Summary of stock option activity
	Number of Options			Weighted Average Exercise Price ($)		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value ($)
Outstanding at December 31, 2020		5,895,570			2.45		5.14		3,376,267
Forfeited		(2,805,571	)		2.74
Outstanding at June 30, 2021		3,089,999			2.18		4.96		4,177,775
Vested and exercisable at June 30, 2021		2,427,499			1.90		4.93		3,972,400


	Six Months Ended
	June 30, 2020
Risk-free interest rate	0.034%	-	1.67%
Expected term in years	3.25	–	4.98
Weighted Avg. Expected Volatility	105.71%	–	106.88%
Expected dividend yield		0%


	Three Months Ended June 30,					Six Months Ended June 30
	2021			2020		2021			2020
Research and development	$	228,625		$	631,876	$	507,438		$	631,876
General and administrative		(29,026	)		954,646		(1,182,601	)		1,420,409
Total	$	(199,599	)	$	1,586,522	$	(675,163	)	$	2,052,285

Three and Six Months Ended June 30, 2021

XML 20 R10.htm IDEA: XBRL DOCUMENT

Leases

6 Months Ended

Jun. 30, 2021

Leases [Abstract]

Leases

Note 4. Leases

The Company’s existing Lease is not subject to any restrictions or covenants which preclude its ability to pay dividends, obtain financing, or enter into additional Lease’s.

As of June 30, 2021, the Company has not entered into any leases which have not yet commenced which would entitle the Company to significant rights or create additional obligations.

The Company does not have any finance leases.

Supplemental lease information as of June 30, 2021:


	As of June 30, 2021			As of December 31, 2020

Operating lease right-of-use asset	$	53,492		$	79,462

Current maturities of operating lease	$	51,132		$	51,125
Non-current operating lease		4,433			28,607
Total operating lease liabilities	$	55,565		$	79,732

Weighted Average remaining lease term (in years):		1.09			1.6
Discount rate:		7.0	%		7.0	%
Right-of-use asset obtained in exchange for lease obligation				$	98,402

Supplemental cash flow information for the six months ended June 30, 2021:

Cash paid for amount included in the measurement of lease liabilities for operating lease

26,136

Schedule of future lease payments
Years ending December 31, 2021,
2021 (Remaining)	$	26,652
2022		31,213
Total future minimum lease payments		57,864
Less imputed interest		(2,299	)
Total	$	55,565

XML 21 R11.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Jun. 30, 2021

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 5. Commitments and Contingencies

Stem Cell Systems

SEC Complaint

Class Action Complaints

XML 22 R12.htm IDEA: XBRL DOCUMENT

Related Party Transactions

6 Months Ended

Jun. 30, 2021

Related Party Transactions

Note 6. Related Party Transactions

XML 23 R13.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jun. 30, 2021

Subsequent Events [Abstract]

Subsequent Events

Note 7. Subsequent Events

Management has reviewed material events subsequent of the period ended June 30, 2021 and prior to the filing of financial statements in accordance with FASB ASC 855 “Subsequent Events”.

XML 24 R14.htm IDEA: XBRL DOCUMENT

Organization, Overview of Operations, Basis of Presentation, Liquidity, Recent Accounting Standards and Earnings (Loss) Per Share (Policies)

6 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Organization

Organization

Overview of Operations

Overview of Operations

Basis of Presentation

Basis of Presentation

Liquidity

Liquidity

Recent Accounting Standards

Recent Accounting Standards

Earnings (Loss) Per Share

Earnings (Loss) Per Share

Following is the computation of basic and diluted net loss per share for the three and six months ended June 30, 2021 and 2020:


	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2021			2020			2021			2020
Basic and Diluted EPS Computation
Numerator:
Loss available to common stockholders'	$	(911,961	)	$	(3,011,593	)	$	(1,429,203	)	$	(4,186,346	)
Denominator:
Weighted average number of common shares outstanding		87,352,364			87,352,364			87,352,364			87,352,364
Basic and diluted EPS	$	(0.01	)	$	(0.03	)	$	(0.02	)	$	(0.05	)

The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:
Stock options		3,089,999			4,788,071			3,089,999			4,788,071
Warrants		12,296,912			12,296,912			12,296,912			12,296,912
Total shares not included in the computation of diluted losses per share		15,386,911			17,084,983			15,386,911			17,084,983

XML 25 R15.htm IDEA: XBRL DOCUMENT

Organization, Overview of Operations, Basis of Presentation, Liquidity, Recent Accounting Standards and Earnings (Loss) Per Share (Tables)

6 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Summary of computation of basic and diluted net loss per share


	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2021			2020			2021			2020
Basic and Diluted EPS Computation
Numerator:
Loss available to common stockholders'	$	(911,961	)	$	(3,011,593	)	$	(1,429,203	)	$	(4,186,346	)
Denominator:
Weighted average number of common shares outstanding		87,352,364			87,352,364			87,352,364			87,352,364
Basic and diluted EPS	$	(0.01	)	$	(0.03	)	$	(0.02	)	$	(0.05	)

The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:
Stock options		3,089,999			4,788,071			3,089,999			4,788,071
Warrants		12,296,912			12,296,912			12,296,912			12,296,912
Total shares not included in the computation of diluted losses per share		15,386,911			17,084,983			15,386,911			17,084,983

XML 26 R16.htm IDEA: XBRL DOCUMENT

Prepaid Expenses (Tables)

6 Months Ended

Jun. 30, 2021

Prepaid Expenses

Prepaid Expenses

Prepaid Expenses
	June 30,		December 31,
	2021		2020
Prepaid insurance	$	-	$	54,180
Prepaid stock options for services		87,001		86,999
Prepaid professional fees		65,000		65,000
Prepaid research and development expense		296,196		289,746
Other prepaid costs		18,271		70,350
Total prepaid expenses	$	466,468	$	566,275

XML 27 R17.htm IDEA: XBRL DOCUMENT

Equity (Tables)

6 Months Ended

Jun. 30, 2021

Equity Method Investments and Joint Ventures [Abstract]

Summary of warrants outstanding

Summary of warrants outstanding
	Shares of Common Stock Issuable from Warrants Outstanding as of				Weighted
	June 30,		December 31,		Average
Description	2021		2020		Exercise Price		Expiration
Series E		584,416		584,416	$	1.54	September 9, 2021
Series F		7,246		7,246	$	3.45	February 23, 2022 & March 9, 2022
Series G		460,250		460,250	$	2.68	July 21, 2022
Series H		910,000		910,000	$	2.75	October 16, 2022
Series I		10,335,000		10,335,000	$	2.00	November 26, 2025
Total		12,296,912		12,296,912

Summary of stock option activity

Summary of stock option activity
	Number of Options			Weighted Average Exercise Price ($)		Weighted Average Remaining Contractual Term (years)		Aggregate Intrinsic Value ($)
Outstanding at December 31, 2020		5,895,570			2.45		5.14		3,376,267
Forfeited		(2,805,571	)		2.74
Outstanding at June 30, 2021		3,089,999			2.18		4.96		4,177,775
Vested and exercisable at June 30, 2021		2,427,499			1.90		4.93		3,972,400

Summary of assumption of stock option activity


	Six Months Ended
	June 30, 2020
Risk-free interest rate	0.034%	-	1.67%
Expected term in years	3.25	–	4.98
Weighted Avg. Expected Volatility	105.71%	–	106.88%
Expected dividend yield		0%

Summary of consolidated statement of operations


	Three Months Ended June 30,					Six Months Ended June 30
	2021			2020		2021			2020
Research and development	$	228,625		$	631,876	$	507,438		$	631,876
General and administrative		(29,026	)		954,646		(1,182,601	)		1,420,409
Total	$	(199,599	)	$	1,586,522	$	(675,163	)	$	2,052,285

XML 28 R18.htm IDEA: XBRL DOCUMENT

Leases (Tables)

6 Months Ended

Jun. 30, 2021

Leases [Abstract]

Schedule of supplemental lease information


	As of June 30, 2021			As of December 31, 2020

Operating lease right-of-use asset	$	53,492		$	79,462

Current maturities of operating lease	$	51,132		$	51,125
Non-current operating lease		4,433			28,607
Total operating lease liabilities	$	55,565		$	79,732

Weighted Average remaining lease term (in years):		1.09			1.6
Discount rate:		7.0	%		7.0	%
Right-of-use asset obtained in exchange for lease obligation				$	98,402

Supplemental cash flow information for the six months ended June 30, 2021:

Cash paid for amount included in the measurement of lease liabilities for operating lease

26,136

Leases (Details 1)

Schedule of future lease payments
Years ending December 31, 2021,
2021 (Remaining)	$	26,652
2022		31,213
Total future minimum lease payments		57,864
Less imputed interest		(2,299	)
Total	$	55,565

XML 29 R19.htm IDEA: XBRL DOCUMENT

Organization, Overview of Operations, Basis of Presentation, Liquidity, Recent Accounting Standards and Earnings (Loss) Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Numerator:
Loss available to common stockholders'	$ (911,961)	$ (3,011,593)	$ (1,429,203)	$ (4,186,346)
Denominator:
Weighted average number of common shares outstanding	87,352,364	87,352,364	87,352,364	87,352,364
Basic and diluted EPS	$ (0.01)	$ (0.03)	$ (0.02)	$ (0.05)
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:
Total shares not included in the computation of diluted losses per share	15,386,911	17,084,983	15,386,911	17,084,983
Share-based Payment Arrangement [Member]
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:
Total shares not included in the computation of diluted losses per share	3,089,999	4,788,071	3,089,999	4,788,071
Warrant [Member]
The shares listed below were not included in the computation of diluted losses per share because to do so would have been antidilutive for the periods presented:
Total shares not included in the computation of diluted losses per share	12,296,912	12,296,912	12,296,912	12,296,912

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

XML 30 R20.htm IDEA: XBRL DOCUMENT

Organization, Overview of Operations, Basis of Presentation, Liquidity, Recent Accounting Standards and Earnings (Loss) Per Share (Details Narrative) - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Par or Stated Value Per Share	$ 0.00001	$ 0.00001
Common Stock, Shares, Issued	87,352,364	87,352,364
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Outstanding	0	0
Cash	$ 4,342,978	$ 7,412,969	$ 10,258,068	$ 12,185,248
Working capital	$ 4,592,838

XML 31 R21.htm IDEA: XBRL DOCUMENT

Prepaid Expenses (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Prepaid Expenses
Prepaid insurance		$ 54,180
Prepaid stock options for services	87,001	86,999
Prepaid professional fees	65,000	65,000
Prepaid research and development expense	296,196	289,746
Other prepaid costs	18,271	70,350
Total prepaid expenses	$ 466,468	$ 566,275

XML 32 R22.htm IDEA: XBRL DOCUMENT

Equity (Details) - $ / shares	6 Months Ended
Equity (Details) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Series E [Member]
Class of Warrant or Right [Line Items]
Shares of Common Stock Issuable from Warrants Outstanding	584,416	584,416
Weighted Average Exercise Price	$ 1.54
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Sep. 09, 2021
Series F [Member]
Class of Warrant or Right [Line Items]
Shares of Common Stock Issuable from Warrants Outstanding	7,246	7,246
Weighted Average Exercise Price	$ 3.45
Series F [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Feb. 23, 2022
Series F [Member] \| Maximum [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Mar. 09, 2022
Series G [Member]
Class of Warrant or Right [Line Items]
Shares of Common Stock Issuable from Warrants Outstanding	460,250	460,250
Weighted Average Exercise Price	$ 2.68
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Jul. 21, 2022
Series H [Member]
Class of Warrant or Right [Line Items]
Shares of Common Stock Issuable from Warrants Outstanding	910,000	910,000
Weighted Average Exercise Price	$ 2.75
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Oct. 16, 2022
Series I [Member]
Class of Warrant or Right [Line Items]
Shares of Common Stock Issuable from Warrants Outstanding	10,335,000	10,335,000
Weighted Average Exercise Price	$ 2.00
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Nov. 26, 2025
Warrant [Member]
Class of Warrant or Right [Line Items]
Shares of Common Stock Issuable from Warrants Outstanding	12,296,912	12,296,912

XML 33 R23.htm IDEA: XBRL DOCUMENT

Equity (Details 1) - USD ($)	6 Months Ended	12 Months Ended
Equity (Details 1) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]
Options outstanding - beginning balance	5,895,570
Weighted Average Exercise Price, Options outstanding - beginning balance	$ 2.45
Options outstanding	4 years 11 months 15 days	5 years 1 month 20 days
Aggregate intrinsic value, Options outstanding - beginning balance	$ 3,376,267
Options forfeited	(2,805,571)
Weighted Average Exercise Price, Options forfeited	$ 2.74
Options oustanding - ending balance	3,089,999	5,895,570
Weighted Average Exercise Price, Options outstanding - ending balance	$ 2.18	$ 2.45
Aggregate intrinsic value, Options oustanding - ending balance	$ 4,177,775	$ 3,376,267
Options Vested and Exercisable	2,427,499
Weighted Average Exercise Price, Options Vested and Exercisable	$ 1.90
Options Vested and Exercisable	4 years 11 months 4 days
Aggregate intrinsic value, Options Vested and Exercisable	$ 3,972,400

XML 34 R24.htm IDEA: XBRL DOCUMENT

Equity (Details 2)	6 Months Ended
Equity (Details 2)	Jun. 30, 2020
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Expected dividend yield	0.00%
Minimum [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Risk-free interest rate	0.034%
Expected life in years	3 years 3 months
Expected Volatility	105.71%
Maximum [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Risk-free interest rate	1.67%
Expected life in years	4 years 11 months 23 days
Expected Volatility	106.88%

XML 35 R25.htm IDEA: XBRL DOCUMENT

Equity (Details 3) - USD ($)	3 Months Ended		6 Months Ended
Equity (Details 3) - USD ($)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Total	$ (199,599)	$ 1,586,522	$ (675,163)	$ 2,052,285
Research and Development Expense [Member] \| Share-based Payment Arrangement, Option [Member]
Total	228,625	631,876	507,438	631,876
General and Administrative Expense [Member] \| Share-based Payment Arrangement, Option [Member]
Total	$ (29,026)	$ 954,646	$ (1,182,601)	$ 1,420,409

XML 36 R26.htm IDEA: XBRL DOCUMENT

Equity (Details Narrative) - USD ($)	3 Months Ended	6 Months Ended
Equity (Details Narrative) - USD ($)	Jun. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	16,668,266	16,668,266
Common Stock, Shares Authorized	500,000,000	500,000,000	500,000,000
Common Stock, Par or Stated Value Per Share	$ 0.00001	$ 0.00001	$ 0.00001
Common Stock, Shares, Outstanding	87,352,364	87,352,364	87,352,364
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period		2,805,571
[custom:ReversalOfStockBasedCompensationDueToCommonStockPurchaseOptionCancellation]	$ 66,130	$ 1,248,575
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 265,726	$ 639,541
N 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures		20,000,000
Stock options grant description		The 2013 Plan is administered by the Board or a committee designated by the Board. Subject to the provisions of the 2013 Plan, the Board has the authority to determine the officers, employees and consultants to whom options will be granted, the number of shares covered by each option, vesting rights and the terms and conditions of each option that is granted to them; however, no person may be granted options to purchase more than 2,000,000 shares in any one fiscal year under the 2013 Plan, and the aggregate fair market value (determined at the time the option is granted) of the shares with respect to which incentive stock options are exercisable for the first time by an optionee during any calendar year cannot exceed $100,000. Options granted pursuant to the 2013 Plan are exercisable no later than ten years after the date of grant.
Excecise price per share limit		not be less than 110% of the fair market value.

XML 37 R27.htm IDEA: XBRL DOCUMENT

Leases (Details) - USD ($)	6 Months Ended
Leases (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease right-of-use asset	$ 53,492	$ 79,462
Current maturities of operating lease	51,132	51,125
Non-current operating lease	4,433	28,607
Total operating lease liabilities	$ 55,565	$ 79,732
Weighted Average remaining lease term (in years):	1 year 1 month 2 days	1 year 7 months 6 days
Discount rate	7.00%	7.00%
Right-of-use asset obtained in exchange for lease obligation	$ 98,402

XML 38 R28.htm IDEA: XBRL DOCUMENT

Leases (Details 1) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Leases [Abstract]
2021 (Remaining)	$ 26,652
2022	31,213
Total future minimum lease payments	57,864
Less imputed interest	(2,299)
Total	$ 55,565	$ 79,732

XML 39 R29.htm IDEA: XBRL DOCUMENT

Leases (Details Narrative)	6 Months Ended
Leases (Details Narrative)	Jun. 30, 2021 USD ($)
Leases [Abstract]
Base rent for First year	$ 4,356
Base rent for Second year	$ 4,459
Lessee, Operating Lease, Term of Contract	2 years

XML 40 R30.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Related Party Transaction [Line Items]
Litigation Settlement, Expense	$ 128,000	$ 122,000	$ 248,000	$ 199,000
Stem Cell Systems [Member]
Related Party Transaction [Line Items]
Debt Instrument, Periodic Payment			$ 27,000

XML 41 R31.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 22, 2018	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Vector Asset Management, Inc [Member]
Related Party Transaction [Line Items]
Share-based Payment Arrangement, Expense	$ 120,000
[custom:PaymentOfCompensationDescription]	per year. On July 1, 2020 the Company amended the ECA and paid VAMI $4,000 per month through November 30, 2020 and $200 per month thereafter until May 31, 2021 at which time the ECA as amended expired.
Costs and Expenses, Related Party		$ 400	$ 30,000	$ 1,000	$ 60,000
Stephen Yan-Klesson
Related Party Transaction [Line Items]
Related Party Costs			$ 5,287		$ 10,811

- Definition

Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

+ Details

EXCEL 42 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end